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The visual photo-transduction cascade is a prototypical G protein-coupled 
receptor (GPCR) signaling system, in which light-activated rhodopsin, the GPCR, 
catalyzes the exchange of GDP for GTP on the heterotrimeric G protein transducin. This 
results in the dissociation of transducin into its component GTP-bound α subunit and the 
βγ subunit complex. Structural information for the rhodopsin-transducin complex will be 
essential for understanding the molecular mechanism of visual photo-transduction. 
Moreover, it will shed light on how GPCRs selectively couple to and activate their G 
protein signaling partners. I have purified a stable detergent-solubilized complex between 
rhodopsin and transducin. The complex was formed on native rod outer segment 
membranes upon light activation, solubilized in lauryl maltose neopentyl glycol (LMNG) 
detergent, and purified with a combination of affinity and size exclusion chromatography. 
The complex is fully functional, with the stoichiometry of rhodopsin to transducin being 
1:1. The molecular weight of the complex was calculated from small angle X-ray 
scattering (SAXS) data and is in good agreement with a model consisting of one 
rhodopsin molecule and one transducin molecule. The complex was visualized by 
negative-stain electron microscopy (EM), which revealed an overall architecture similar 
to that of the β2 adrenergic receptor-GS complex including a flexible helical domain in 
the transducin α subunit. The monodispersity, stability, and high yield of the purified 
complex allowed for further efforts toward obtaining a high-resolution structure of this 
important signaling complex. 
Recent X-ray and cryo-electron microscopy (cryo-EM) structures of complexes 
between different GPCRs and the stimulatory GS protein have revealed how these 
receptors converge structurally at the cytoplasmic end and engage the same GS protein, 
whereas, the cryo-EM structures of two GPCR-Gi protein complexes show how the 
inhibitory Gi protein binds receptors in a different manner than the GS protein. In order to 
further our understanding of the mechanisms that underlie the specificity of GPCR-G 
protein interactions, and how they result in the G protein activation event, we determined 
a high-resolution cryo-EM structure of the light-activated, native bovine rhodopsin 
complexed with its cognate G protein partner transducin, which belongs to the inhibitory 
Gi family. The outward movement of transmembrane helix (TM) 6 and the rearrangement 
of TM5 at the intracellular side of Rho open up a binding cleft for the transducin α 
subunit, which engages rhodopsin in a different orientation than previously observed in 
other GPCR-GS protein complexes. The orientation of GT is also different from that of 
the Gi protein in the recently reported GPCR-Gi complexes, revealing the unexpected 
diversity regarding how GPCRs engage their G protein partners, even within the same G 
protein family. Moreover, the helical domain of the GαT subunit is less flexible than those 
resolved in previous GPCR-G protein complex structures and adopts an open 
conformation contacting the transducin β subunit, thus shedding new light on its 
involvement in the G protein activation event. 
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Chapter 1 
 
Introduction 
 
1.1 Vertebrate visual phototransduction 
Cells, the minimal functional unit of all living organisms, are separated from their 
outside environment by the membrane boundary. The ability to sense and respond to 
extracellular signals and the capability of inter-cellular communications are essential for 
the survival and prosperity of all living beings. This is typically achieved through the so-
called signal transduction triad (receptor-transducer-effector) involving transmembrane 
receptor proteins that convey outside stimuli across the plasma membrane and the 
resulting signals are relayed and amplified in the cytoplasm by transducer and effector 
molecules leading to appropriate cellular responses1. The visual phototransduction 
machinery in vertebrates is a classic example of such a process. Retinal rod cells are 
highly differentiated neurons that are responsible for the detection of light (Fig. 1a). They 
are so exquisitely sensitive that the signal from just a single photon can be detected2,3. 
The rod cells are separated into two compartments, the inner and outer segments, by a 
cilium structure. The rod outer segment (ROS) contains stacks of tightly packed lipid 
bilayer discs that are enclosed by the rod cell plasma membrane and the disc membranes 
are highly enriched with proteins that are involved in phototransduction (Fig. 1b), namely 
the receptor rhodopsin, the transducer tranducin and the effector cGMP 
phosphodiesterase (PDE6). The receptor rhodopsin is composed of its protein moiety 
opsin and a covalently bound chromophore 11-cis retinal. Absorption of a single photon 
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triggers the cis-trans isomerization of retinal, which causes a series of structural changes 
in opsin, ultimately converting the receptor from an inactive state to an activated 
signaling state, termed Metarhodopsin II (Meta II), within one millisecond. Transducin is 
a guanine nucleotide binding protein (G protein) that is GDP-bound in its inactive state. 
Metarhodopsin II activates transducin by catalyzing the exchange of its nucleotide GDP 
for GTP. The effector molecule PDE6 contains two non-identical catalytic subunits αPDE 
and βPDE, which are kept inactive by two inhibitor γPDE subunits. The GTP-bound 
transducin can bind to γPDE subunits and displace them from the catalytic subunits, thus 
alleviating the inhibition and turning on the cGMP hydrolysis activity of PDE6. The 
activation of PDE6 lowers cGMP levels in the cytosol. On the rod cell plasma membrane, 
there are non-gated potassium channels maintaining an ongoing outward K+ current, 
which tends to hyperpolarize the photoreceptor cell. There are also cGMP-gated sodium 
channels on the ROS plasma membrane, which are kept open by the high cGMP 
concentration in the dark, allowing an inward flux of Na+ that maintains the rod 
photoreceptor cells in a partially depolarized state. Depletion of cGMP by PDE6 leads to 
closure of these cGMP-gated channels, resulting in the hyperpolarization of the rod cell 
membrane. This hyperpolarization slows down the release of the neurotransmitter 
glutamate from the synaptic terminal and leads to visual neural responses.4,5 
The signal from light is amplified in every step of the phototransduction cascade. 
One photon is sufficient to convert one rhodopsin molecule to its Meta II state, which can 
activate hundreds of transducin molecules per second6. Activated transducin then binds 
and stimulates PDE6 in a 1:1 or 2:1 stoichiometry7 and each activated PDE6 can 
hydrolyze thousands of cGMP second messenger molecules per second8.  
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Figure 1.1 Vertebrate visual phototransduction. a, Diagram of a rod photoreceptor 
cell. b, Schematic representation of the receptor-transducer-effector triad in visual 
phototranduction signaling cascade. 
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The final stage of amplification is achieved on the cGMP-gated channels. The binding of 
cGMP on these channels is positively cooperative with a Hill coefficient of about 3 for 
channel opening9. Thus the decrease of cGMP concentration is amplified about 3-fold in 
the decrease of the inward Na+ current.  
 
1.2 The G protein-coupled receptor superfamily 
The vertebrate visual phototransduction pathway is a classic G protein-coupled 
receptor (GPCR) signaling cascade, in which the photoreceptor rhodopsin is a 
prototypical member of the GPCR family of transmembrane proteins. GPCRs constitute 
the largest group of membrane receptors in humans with over 800 members10. They are 
involved in detecting and transducing signals from an extremely diverse range of 
extracellular stimuli, including photons, odorants, hormones and neurotransmitters11. 
GPCRs share a signature structural motif of seven transmembrane α helices (TM) with an 
extracellular N-terminal domain and an intracellular C terminus. The 7TM bundle 
conveys signals of ligand binding (ligand photoisomerization in the case of rhodopsin) on 
the extracellular side to conformational changes on its cytoplasm surface, allowing for 
binding and activation of heterotrimeric G proteins. Based on similarities in sequence and 
structural features, GPCRs can be classified into five main families, namely rhodopsin, 
secretin, glutamate, adhesion and frizzled/taste212. The rhodopsin-like GPCRs represent 
the largest and most studied group with about 700 members. They differ from other 
GPCR family members in having a much smaller N terminus and most of the rhodopsin-
like GPCRs contain an NPxxY motif on TM7 and a DRY motif on the cytoplasm end of 
TM3, which are important for receptor stabilization and G protein activation13. The 
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secretin-like receptors have a large N terminus containing multiple conserved cysteine 
bridges that are important for ligand binding and they respond to relatively large peptide 
hormones, such as glucagon and parathyroid hormone12. The glutamate-family receptors 
form obligate dimers and have large extracellular ligand-binding domains that form a 
‘Venus flytrap’ structure14. This family includes the metabotropic receptors for gamma-
aminobutyric acid (GABA) and glutamate. Members of the adhesion family contain 
adhesion-like motifs in the N terminus, such as epidermal growth factor (EGF)-like 
repeats and mucin-like regions, which are likely to mediate cell-cell adhesion15. In 
addition, they also have GPCR autoproteolysis-inducing (GAIN) domains on the 
extracellular side that have been shown to modulate receptor activity16. The frizzled 
receptors play crucial roles in developmental biology by transmitting signals from the 
Wnt family of secreted glycoproteins, which bind to the Cys-rich N-terminal domain of 
these receptors17. As a result of the wide-ranging roles played by GPCRs in human 
physiology, GPCRs are very effective drug targets with over one third of small-molecule 
pharmaceuticals today targeting this receptor superfamily18. 
 
1.3 Heterotrimeric G proteins 
G proteins act as binary signaling switches by alternating between two states: the 
inactive GDP-bound “off” state and the active GTP-bound “on” state19. There are two 
major classes of G proteins: the Ras-related monomeric small G proteins20 and the large 
heterotrimeric G proteins21. The heterotrimeric G proteins are composed of three 
subunits: the guanine nucleotide binding α subunit and the constitutively associated β and 
γ subunits. The α subunit of heterotrimeric G proteins shares a homologous GTPase 
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domain with small G proteins. However, they differ from Ras-like small G proteins in 
that the α subunit contains an additional helical domain that forms a clamshell structure 
over the nucleotide-binding pocket and the GDP-bound α subunit exists in a heterotrimer 
with the βγ subunits. Activated GPCRs act as guanine nucleotide exchange factors for 
heterotrimeric G proteins and promote the dissociation of GDP from the nucleotide-
binding pocket. The resulting high-affinity ligand-GPCR-nucleotide-free G protein 
ternary complex forms the active state of GPCR signaling. As the concentration of GTP 
is much higher than GDP in physiological conditions, GTP can enter the pocket and its 
binding causes structural changes in the α subunit, lowering its affinity for both βγ 
subunits and the receptor and resulting in the dissociation of the active-state complex. 
The GTP-bound α subunit and sometimes the free βγ subunits can engage their 
downstream effectors to turn on signaling. As the α subunits has an intrinsic GTP 
hydrolysis activity, which can be further promoted through binding to the regulator of G 
protein signaling (RGS) proteins, the G protein signaling is terminated with the 
conversion of GTP to GDP. The GDP-bound α subunit reassociates with βγ subunits to 
form the inactive-state heterotrimer, thus completing the G protein cycle (Fig. 1.2). 
In contrast to the striking diversity of the GPCR superfamily there is only a 
relatively small number of heterotrimeric G proteins to relay the signals to downstream 
effectors. In humans, there are 21 α subunits encoded by 16 genes, 6 β subunits encoded 
by 5 genes, and 12 γ subunits22. Several different βγ subunits can interact with the same α 
subunit isoform, suggesting that subcellular localization and expression levels can be 
important in modulating G protein signaling23. Based on amino acid sequence similarity 
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in the α subunit, heterotrimeric G proteins can be classified into four main families: GS, 
Gi, Gq and G1224.  
One of the best-characterized G proteins is the retinal rod transducin, which belongs to 
the inhibitory Gi family. X-ray crystal structures have been solved for the transducin α 
subunit in both the GDP-bound25 and the GTP-bound26 states, as well as in its GTP 
hydrolysis transition state27. In addition, structures of the transducin heterotrimer28 and 
the transducin α subunit in complex with both its GTPase-activating protein (GAP) RGS9 
and a peptide fragment of the effector PDE629 have been determined. These structures 
have provided mechanistic details of how the transducin α subunit is associated with βγ 
subunits in the inactive state, how it engages the downstream effector and how the 
signaling is turned off through GTP hydrolysis. The GTPase domain of the α subunit is 
structurally very similar to the overall architecture of Ras-like small G proteins and 
contains five α helices (α1-α5) surrounding a six-stranded β sheet (β1-β6) (Fig. 1.3a). It 
forms the nucleotide-binding pocket by providing the consensus nucleotide-binding 
sequences found in all G proteins, such as the NKxD motif and the TCAT motif for 
guanine ring binding and the DxxG Mg2+ binding motif. The helical domain is connected 
to the GTPase domain through two flexible linkers and has a rigid α-helical structure with 
a long central helix (αA) surrounded by five shorter helices (αB-αF). It forms a lid over 
the nucleotide-binding pocket burying nucleotides in the core of the α subunit and helps 
to reduce any spontaneous nucleotide exchange in the absence of an activated receptor. In 
addition, the helical domain also acts as a built-in GAP domain that provides a key Arg 
residue, termed the arginine finger, which stabilizes the transition state for GTP 
hydrolysis and facilitates the release of GTP γ phosphate. 
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Figure 1.2 The G protein cycle. An activated GPCR engages a heterotrimeric G protein 
and promotes GDP dissociation from the α subunit, forming the active-state ternary 
complex. GTP binding to the α subunit causes dissociation of the complex and the GTP-
bound α subunit and the free βγ subunits then engage downstream effectors to turn on 
signaling. Due to the intrinsic GTPase activity of the the α subunit, GTP is converted 
back to GDP over time and the GDP-bound α re-associates with βγ to reform the 
heterotrimer. 
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Comparisons between the inactive and active state structures of the α subunit have 
revealed that there are three flexible loops, designated switches I, II and III, in the 
GTPase domain that undergo significant structural changes upon nucleotide exchange 
(Fig. 1.3b). These conformational changes are initiated by the direct contact of conserved 
residues in Switch I and II with the terminal γ phosphate of GTP. These changes are then 
propagated through a series of conformational transitions to Switch III, which is a unique 
feature in heterotrimeric G proteins and is involved in effector activation. The β subunit 
is composed of seven WD40 sequence repeats that form a seven-bladed β-propeller 
structure in the core of the protein (Fig. 1.3a). The N terminus of the β subunit forms an α 
helix that is involved in a coiled-coil interaction with the N terminus of the γ subunit, 
with the C terminus of γ further contributing to the interaction by binding to the β-
propeller core of the β subunit. In the GDP-bound inactive state, the α subunit interacts 
with the βγ subunits through its N-terminal helix and a hydrophobic pocket formed by 
switches I and II. Both the α and γ subunits are lipid-modified. All α subunits, with the 
exception of transducin, are palmitoylated at the N terminus and members of the Gi 
family also have N-terminal myristoylation30. All γ subunits undergo post-translational 
isoprenylation at the C terminus with either a farnesyl (Gγ1, Gγ8 and Gγ11) or 
geranylgeranyl (all others) moiety31. The N terminus of the α subunit and the C terminus 
of the γ subunit are in close proximity with each other and the lipid modifications help to 
increase the affinity between the α and the βγ subunits and facilitate the localization of 
the heterotrimer to the membrane32. 
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Figure 1.3 G protein structures. a, Structure of the transducin heterotrimer (PDE 
1GOT). The α GTPase domain is colored green, the α helical domain is yellow, the β 
subunit is cyan, the γ subunit is magenta and the switches I, II and III are red. b, 
Comparison between structures of transducin α subunit in GDP-bound (grey) and GTP-
bound (green) states. The switches I, II and III are colored red. 
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1.4 GPCR desensitization 
Cells have devised a specialized desensitization mechanism to terminate GPCR 
signaling. Activated receptors can recruit GPCR kinases (GRK), which phosphorylate the 
receptor at its C terminal tail. Phosphorylations on the receptor allows for the high-
affinity recruitment of arrestin33, which engages the receptor first at its the C-tail and 
subsequently binds to the transmembrane core. The latter interaction occludes G protein 
binding on the receptor and therefore sterically prevents further G protein activation34,35. 
Binding of arrestin also initiates receptor internalization through interactions with the 
endocytic machinery36. Furthermore, arrestins also serve as an alternative signaling 
system by acting as adaptors and scaffolds for interactions with numerous other signaling 
molecules, such as Src family nonreceptor tyrosine kinases37 and ERK1/2 MAP kinase 
cascades38. In this distinctive model of GPCR signaling, arrestin binding mediates 
distinct downstream signaling events from the receptor at the same time that it uncouples 
the receptor from activating its cognate G proteins. The finding that arrestin-bound M2 
muscarinic receptors exhibit increased affinity for agonists, but not antagonists, has led to 
the notion that the agonist-receptor-arrestin complex represents an “alterative ternary 
complex”39. Interestingly studies on the secretin-family GPCRs have shown that they are 
able to promote sustained G protein signaling despite their tight interaction with 
arrestin40,41. More recently, negative-stain electron microscopy studies have provided 
direct evidence that these receptors are capable of simultaneously interacting with both 
arrestin and G protein, forming a “megacomplex”42. Taken together, GPCR signaling has 
proven to be far more complex than the canonical receptor-G protein pathway. 
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1.4 GPCR X-ray crystallography 
As GPCRs are capable of sensing diverse ligands and regulating multiple 
signaling pathways, GPCRs have evolved to be structurally dynamic and adopt various 
flexible conformations. As a result, they are biochemically unstable once extracted from 
their native lipid bilayer environment and are very challenging targets for structural 
studies. The first structural image of a GPCR was obtained in the 1990s with dark-state 
bovine rhodopsin by using electron diffraction with two-dimensional crystals43. This 9Å 
structure revealed the relative orientation of the seven transmembrane helices in 
rhodopsin and also proved the existence of a folded extracellular domain. However, due 
to the low resolution of the structure, amino acid side chains were not resolvable. The 
first high-resolution GPCR structure was solved by X-ray crystallography for dark-state 
rhodopsin in the year 200044. In addition to revealing the previously observed 7TM fold, 
the rhodopsin crystal structure shows that the covalently bound ligand 11-cis retinal is 
buried within the top half of the transmembrane bundle and is further occluded from the 
extracellular side by the N-terminal β-sheet lid, and on the cytoplasm side there is an 
eighth amphipathic helix parallel to the membrane plane. Subsequently, structures of 
rhodopsin in the apo state45, the active all-trans retinal-bound state46 and in complex with 
a G protein α subunit C-terminal peptide46 were also determined. The successes of 
rhodopsin crystallization is largely due to the use of Zn(OAc)2 that precipitates non-
ligand-bound receptors during purification and the addition of the small molecule 
additive heptanetriol that reduces detergent micelle size allowing for exposure of larger 
polar surfaces on the receptor47. However, the methods used for crystallizing rhodopsin 
cannot be easily applied to the structural determination of other GPCRs. Unlike 
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rhodopsin, which can be extracted from native bovine retinae in milligram quantities, 
other GPCRs are not abundant from native sources. Moreover, most GPCRs have long 
flexible loops connecting the transmembrane helices that would hinder crystallization 
efforts and they are also significantly less stable than rhodopsin.  
The determination of the first human GPCR structure, the β2 adrenergic 
receptor48, in 2007 showcased the first generalizable approach for GPCR crystallization 
and ushered in a new era of GPCR structural biology with the number of GPCR 
structures growing rapidly in the following years. As of today, there are over 250 GPCR 
structures for 52 different GPCRs. Two key technological advances have propelled this 
recent explosion of new GPCR structures: novel receptor engineering and lipidic cubic 
phase crystallization. 
The first key technique involves engineering the receptor to allow it to become 
more tractable towards crystallization. There have been two main approaches for GPCR 
engineering, namely T4 lysozyme fusion49 and alanine-scanning thermostabilization50. As 
most GPCRs have large flexible loops, especially the 3rd intracellular loop (ICL3), that 
confers structural heterogeneity to the receptor, which would be problematic in 
crystallization, the T4 lysozyme fusion method involves replacing ICL3 with a stable 
soluble protein such as T4 lysozyme. The distance between the N and C termini of T4 
lysozyme matches the predicted spanning range of ICL3 and improves the rigidity of this 
otherwise flexible region. Moreover, the introduction of the soluble protein significantly 
increases the polar surface on the receptor, which would facilitate crystallographic lattice 
contacts. Although introduction of the bulky T4 lysozyme often blocks receptor-G 
protein interactions, the ligand-binding affinity of the engineered receptor typically 
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remains unaffected, suggesting that the structural features observed in the ligand-binding 
pocket should be unperturbed. Following the initial successes of T4 lysozyme, many 
other fusion partners have been developed and have significantly increased the success 
rate of obtaining high-resolution GPCR structures51. The other approach for GPCR 
engineering involves the use of alanine-scanning mutagenesis coupled with 
thermostability assays so as to identify mutations that increase the thermostability of the 
receptor. The rationale behind this approach is that the melting temperature (Tm) of 
membrane proteins often correlates strongly with their stability in harsh short-chain 
detergents. The introduction of mutations that increase the Tm of the receptor would 
allow it to remain stable for the duration of the crystallization process in short-chain 
detergents, which have small micelles that would expose more hydrophilic surfaces on 
the receptor, allowing it to be crystallized with conventional in surfo vapor diffusion 
methods. This method was first demonstrated in the determination of the turkey β1 
adrenergic receptor structure52 and has subsequently been applied to the crystallization of 
many other GPCRs. And in some challenging cases, both receptor thermostabilization 
and the introduction of a fusion partner in ICL3 have been utilized and have proven that 
the two engineering approaches are compatible with each other53. The engineered GPCRs 
need to be expressed in eukaryotic expression systems, such as Sf9 insect cells, as 
prokaryotes exhibit very low level of functional receptor expression. Recently, a directed 
evolutionary method has been developed to allow for simultaneous screening for 
mutations that allow for both high levels of functional GPCR expression in E. coli and 
increased receptor thermostability, leading to the determination of a GPCR structure in a 
conformation that is distinct from that obtained from previous engineering methods54. 
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The second key technique is lipidic cubic phase crystallography55. It involves 
reconstituting purified detergent-solubilized receptor into a lipid crystalline phase, termed 
the mesophase, of monoacyl glycerol lipids, such as monoolein. During crystallization 
trials, the added precipitant reagents permeate the cubic phase through its bicontinuous 
aqueous channels and induce the formation of local lamella phase patches that act as 
nucleation centers for crystal formation. The surrounding cubic phase serves as a 
reservoir of proteins that feed growing crystals that form through ordered stacking of 
lipid bilayer sheets. This technique was first utilized in the crystallization of 
bateriorhodopsin in the 1990s56, but was not widely adopted at the time, as the lipidic 
cubic phase is difficult to handle due to its high viscosity and there was no efficient high-
throughput method for crystallization screening. The development of the coupled-syringe 
mixing method and crystallization robots capable of dispensing the viscous cubic phase 
has enabled the application of this method to low-yielding precious samples such as 
purified GPCRs57. The typical crystals grown from the cubic phase are very small and are 
often invisible after cryo-cooling. The development of bright mini synchrotron X-ray 
beams and raster-scanning software has been instrumental in enabling structure 
determination with cubic phase crystals58. 
 
1.5 Active-state GPCR structures 
Most of the GPCR structures determined to date are of the inactive antagonist-
bound state. The difficulties in capturing the active-state structure result from the 
increased conformational plasticity of GPCRs upon activation. Early attempts at the 
crystallization of the β2 adrenergic receptor bound to a covalent agonist resulted in a 
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structure that resembled the inactive conformation59, suggesting that the active state does 
not represent the energy minima in such preparations. This has been further supported by 
molecular dynamics simulations, which revealed spontaneous relaxation of the agonist-
bound, activated receptor to the inactive state59. Subsequent biophysical characterizations 
utilizing nuclear magnetic resonance (NMR)60 and electron paramagnetic resonance 
(EPR)61 have shown that high-affinity full agonists alone do not suffice to stabilize the β2 
adrenergic receptor in the active conformation. 
In order to stabilize GPCRs in the active state, nanobodies have been developed 
as a G protein mimetic binding partner for the receptor. Nanobodies are isolated VHH 
domain fragments derived from single-chain camelid antibodies62. Radioligand-binding 
assays have confirmed that nanobodies are capable of increasing the binding affinity of 
agonists to receptors in a similar manner as G proteins. The structural rigidity and small 
size of nanobodies make them ideal crystallization chaperones and the use of a nanobody 
raised against agonist-bound β2 adrenergic receptor, termed Nb80, has allowed for the 
first successful determination of an active-state non-rhodopsin GPCR structure63. In 
addition to being used as a substitute for G proteins in capturing active-state receptors, 
the development of a different nanobody, Nb35, has proven to be instrumental in 
obtaining the first high-resolution GPCR-G protein complex structure, the β2 adrenergic 
receptor-GS protein complex64 (Fig 1.4a). Nb35 was obtained through injecting llamas 
with liposomes embedded with cross-linked β2 adrenergic receptor-GS protein complex. 
Negative-stain electron microscopy (EM) studies have shown that Nb35 binds at the 
interface between α and β subunits of the G protein65. Nb35 significantly improved the 
diffraction quality of the complex crystals and contributed to key crystal lattice contacts.  
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Figure 1.4 Structure of the β2 adrenergic receptor-GS protein complex. a, 
Comparison of the complex structure (PDB 3SN6) with that of the inactive receptor 
(PDB 2RH1, colored grey). T4 lysozyme is colored orange, the activated receptor is red, 
the G protein α subunit is green, the β subunit is cyan, the γ subunit is magenta, and Nb35 
is yellow. b, Comparison between structures of the nucleotide-free complex and the Gi 
heterotrimer (PDB 1GP2, colored grey). 
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Negative-stain EM has also revealed that the helical domain of the G protein α subunit is 
flexible in the receptor-G protein complex and the addition of a pyrophosphate-mimetic 
small molecule foscarnet improved the rigidity of the helical domain65. As T4 lysozyme 
fusion at ICL3 would occlude G protein binding, it was fused directly to the N terminal 
end of TM1 instead replacing the flexible extracellular domain64. The addition of T4 
lysozyme at the extracellular side significantly increased the polar surface on this end of 
the complex and contributed to forming crystallographic contacts. 
The β2 adrenergic receptor-GS protein complex structure reveals that the receptor 
engages with the G protein only through the α subunit. When compared to the inactive 
state structure, the most significant changes in the β2 adrenergic receptor involve a 14Å 
outward movement of the cytoplasmic end of TM6 accompanied by a downward 
extension of TM5 (Fig. 1.4a). These conformational changes open up a binding surface 
for the G protein on the cytoplasmic side of the receptor. The most striking changes in the 
G protein involve the 127° rotation of the helical domain relative to the GTPase domain 
of the α subunit (Fig. 1.4b). Similar domain separation in the active-state complex has 
also been observed in double electron-electron resonance (DEER) spectroscopy studies 
on the rhodopsin-Gi protein complex66. In the nucleotide-free complex, the C terminal α5 
helix of the α subunit extends upward to insert into the cleft opened up by the 
conformational changes in receptor TM5 and TM6 of the receptor (Fig. 1.4b). The α5 
helix connects receptor interaction to the nucleotide-binding pocket through its 
connection to the β6-α5 loop, which contains the conserved TCAT motif for binding the 
guanine base. In addition, the activated β2 adrenergic receptor also interacts with the αN-
β1 loop, which is linked to the GDP β-phosphate binding P-loop through the β1 strand. 
	 23	
Hydrogen-deuterium exchange mass spectrometry (HXMS) studies of the β2 adrenergic 
receptor-GS protein complex have revealed that there is elevated deuterium exchange in 
both the N terminal part of the α5 helix and the β1 strand67, supporting the notion that the 
receptor promotes GDP dissociation by perturbing both the β6-α5 loop and the P-loop. 
 
1.6 Overview of thesis research 
My thesis research started on the heels of the tour de force structure of the β2 
adrenergic receptor-GS protein complex. The ultimate goal is to obtain a high-resolution 
structure of the rhodopsin-transducin complex, which is the GPCR-G protein complex 
involved in vertebrate scotoptic vision. The determination of such a structure would shed 
light on key questions that still surround the mechanisms underlying GPRC-G protein 
interactions. 
The first key question concerns the role of the G protein βγ subunits in the G 
protein activation process. Comparison of the structure of the nucleotide-free GS protein 
to that of the GDP-bound G protein heterotrimer shows that there is little change in the 
conformation of the βγ subunits. The activated β2 adrenergic receptor does not interact 
with the βγ subunits of the GS protein. Therefore, based on the complex structure, it 
seems likely that the function of the βγ subunits is merely to stabilize the N terminus of 
the α subunit and help present the α subunit for engagement with the activated receptor. 
However, a significant amount of earlier biophysical evidence has suggested that the βγ 
subunits may play an active role in G protein activation. Alanine-scanning mutagenesis 
performed on the transducin β subunit has identified several β subunit mutants that 
behave normally in G protein heterotrimer assembly, but are functionally impaired in 
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supporting rhodopsin-catalyzed nucleotide exchange68. Also a farnesylated C-terminal 
peptide of transducin γ subunit has been shown to stabilize the active MetaII state of 
rhodopsin69 and this Gγ peptide forms an amphipathic helix upon interaction with 
activated rhodopsin based on NMR studies70. Therefore, additional GPCR-G protein 
complex structures may reveal features in the βγ subunits that would shed further light on 
their role in GPCR-dependent G protein activation. 
The second key question is how different GPCRs selectively engage their cognate 
G proteins. The β2 adrenergic receptor-GS protein complex still remains the only GPCR-
G protein crystal structure solved to date. In the past few years, with the development of 
direct-electron detectors71 and motion-correction software72, cryo electron microscopy 
(cryo-EM) has emerged as a powerful tool for high-resolution protein structure 
determination. Cryo-EM has been utilized to determine the structures of two secretin-
family GPCRs, the calcitonin receptor73 and the glucagon-like peptide 1 (GLP1) 
receptor74,75, bound to GS proteins. In the past few months, structures of four additional 
complexes between different GPCRs and the inhibitory Gi family proteins, namely the µ-
opioid receptor76, rhodopsin77, and adenosine A1 receptor78 complexed with the Gi 
protein and the serotonin 5-HT1B receptor-GO complex79, have been solved by cryo-EM. 
These recent structures reveal that the GS protein engages different receptors in virtually 
the same conformation and the Gi family proteins interact with activated GPCRs in a 
slightly different orientation than the GS protein. However, the G protein-interacting 
residues on these different receptors are not conserved and there does not seem to be a 
correlation between the existence of specific residues on the receptor and the G protein-
coupling preference. Therefore, the G protein specificity is likely to be determined by 
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more complex three-dimensional topology on the cytoplasmic end of the receptor. 
Additional GPCR-G protein complex structures would be needed to allow for predictions 
of the G protein-coupling preference based on receptor primary sequence. The G protein 
transducin is a member of the inhibitory Gi family and the structure of the rhodopsin-
transducin complex would help to provide further insights into the structural determinants 
of receptor-G protein interaction. 
As described in chapter 2, we have been able to extract a light-activated 
rhodopsin-transducin complex from the native retinal membrane using detergents and 
then purify this complex by using affinity and size exclusion chromatography. The 
resulting rhodopsin-transducin complex is active, as it readily dissociates upon the 
addition of GTP. Negative-stain electron microscopy and small-angle X-ray scattering 
have been utilized to biophysically characterize the purified complex and have revealed 
that the particles are monodisperse and that the helical domain of the transducin α subunit 
adopts flexible open conformations, similar to what has been observed for the β2 
adrenergic receptor-GS complex. 
We have been able to obtain a 4.5Å-resolution structure of the rhodopsin-
transducin complex using cryo-EM, as described in chapter 3. Surprisingly this structure 
reveals that the G protein transducin engages the receptor in an orientation significantly 
different from those in both the GS complex structures and other Gi complex structures. 
Furthermore, our structure points to a possible interaction between the G protein α helical 
domain and the β subunit, which may play an active role in G protein activation. 
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Chapter 2 
* 
Isolation and Structure-function Characterization of  
the Rhodopsin-Transducin Complex  
 
 
INTRODUCTION 
G protein-coupled receptors (GPCRs), the largest family of transmembrane proteins, 
are the targets for nearly 50% of all pharmaceutical drugs (1). These receptors modulate 
cellular responses to a vast array of extracellular signals through the activation of 
heterotrimeric G proteins, with the active state being defined as the complex that forms 
between the agonist-bound (or light-stimulated) GPCR and nucleotide-free G protein (2). 
Attempts to obtain structural information for GPCRs, and especially for signaling-active 
GPCR-G protein complexes, have garnered a great deal of interest, both as a means to 
better understand the underlying mechanisms by which this important family of receptors 
mediates a wide range of biological outcomes, and as a critical step in the design of more 
selective and effective drug treatments. Recent technological advancements, including 
novel protein engineering (3), in meso crystallization (4) and micro-focus beamlines at 
synchrotron facilities (5), have ushered in significant progress in the determination of 
high-resolution GPCR structures. However, only a few of those structures are of activated 
GPCRs, and thus far, only two GPCR-G protein complex structures have been solved, 
namely that of the β2-adrenergic receptor-GS protein complex (6), and the calcitonin 
receptor-GS protein complex (7). Furthermore, virtually all of these structures, with the 																																																								
This chapter is adapted from an article originally published in the Journal of Biological Chemistry.  
Gao, Y. et al. Isolation and structure–function characterization of a signaling-active rhodopsin–G protein 
complex. J. Biol. Chem. 292, 14280–14289 (2017). 
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exception of rhodopsin, have been obtained with GPCRs which were heavily modified so 
as to facillitate crystallization. Therefore, to help fully understand the mechanisms of 
GPCR-mediated G protein activation, it will be important to obtain structural information 
of active complexes formed between native receptors and their different G protein 
partners. 
Rhodopsin, the photoreceptor responsible for dim light vision, is a prototypical 
member of the GPCR superfamily. Absorption of a single photon by rhodopsin activates 
many transducin (GT) molecules (the subunits designated as αT, β1, and γ1) in less than a 
second, generating GTP-bound αT subunits that activate the effector enzyme, cGMP 
phosphodiesterase (PDE) (8). The photo-transduction system offers certain advantages 
for obtaining structural insights into GPCR-signaling, as its principle components can be 
purified from native tissue in large quantities. As a result, rhodopsin represents the first 
and only GPCR for which X-ray crystal structures (9-13) have been solved in the native 
form.  
The determination of an X-ray crystal structure of an activated rhodopsin-transducin 
complex not only is essential to providing a comprehensive picture of photo-transduction, 
but also for obtaining a better understanding of how the specificity between GPCRs and 
G proteins is achieved, as well as establishing the stoichiometry of the GPCR-G protein 
complex in the signaling-active state.  In order to facilitate future crystallographic studies, 
here we describe a milligram-scale purification of an active rhodopsin-G protein complex 
formed with native light-activated rhodopsin (Rho) and a GαT/Gαi1 chimera (αT) together 
with the retinal β1 and γ1 subunits (GT). The resulting complex is stable and 
homogeneous, and the stoichiometry between Rho and GT is 1:1, as determined by both 
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UV/Vis spectroscopy and radiolabeled nucleotide binding. Small angle X-ray scattering 
(SAXS) studies conducted with the purified Rho-GT complex further confirm that the 
complex is monodisperse, and molecular weight values calculated based on SAXS data 
suggest that the complex is composed of a monomeric Rho bound to one GT molecule. 
Negative-stain electron microscopy (EM) analyses of the complex confirm its 
homogeneity and reveal an overall architecture that is reminiscent of both EM (14) and 
crystallographic (6) results of the β2-adrenergic receptor-GS protein complex. 
 
RESULTS 
Detergent selection for Rho-GT complex purification 
In order to purify the Rho-GT complex, a suitable detergent is needed not only to 
extract the complex from its native rod outer segment membrane, but also to maintain its 
stability. The first crystal structures of rhodopsin were solved using receptor solubilized 
in short-chain detergents, such as nonylglucoside (9), C8E4 (10), and octylglucoside (11-
13). Although these detergents can maintain the stability of dark inactivated rhodopsin 
for several days, the complex formed with light-activated rhodopsin and transducin 
cannot survive the extraction process and dissociates quickly upon solubilization. 
Therefore, we set out to select a detergent in which the Rho-GT complex would remain 
stably associated.  
A fluorescence assay, monitoring the change in the intrinsic tryptophan fluorescence 
of αT upon nucleotide exchange (15), was utilized to examine the rhodopsin-catalyzed 
nucleotide exchange activity in various detergents. When αT exchanges GDP for GTPγS, 
a non-hydrolyzable GTP analog, there is an increase in the intrinsic tryptophan 
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fluorescence due to a conformational change in the Switch II region, one of three regions 
of αT that change conformation upon GTP binding.  Therefore, the rate of Rho-catalyzed 
nucleotide exchange can be used to assay the activity of Rho under various detergent 
conditions. Commercially available detergents from the maltoside and maltose neopentyl 
glycol (MNG) (16) families were tested. Most of these detergents were able to maintain 
the Rho-catalyzed nucleotide exchange activity at higher concentrations than their 
corresponding critical micelle concentration (i.e. 2 × CMC), with a rate constant of ~3 
min-1 (Figs. 2.1A and 2.1B).  There is a clear dependence of Rho activity on the length of 
the detergent hydrophobic chain. However, when using detergent concentrations above or 
below 2 × CMC, the Rho-stimulated nucleotide exchange activity in most of the tested 
detergents decreased significantly (Fig. 2.1C, see dodecyl maltoside), suggesting that 
these detergents are not well-suited for extracting the complex from rod outer segment 
(ROS) membranes, for which an initial high detergent concentration (typically around 1% 
w/v) would be required. Of the various detergents tested, only LMNG (lauryl maltose 
neopentyl glycol) was able to maintain high Rho-stimulated nucleotide exchange activity 
at various concentrations (Fig. 2.1D) and was therefore selected to be used for Rho-GT 
complex purification. 
 
Purification of the Rho-GT complex 
The purification scheme for the Rho-GT complex is illustrated in Fig. 2.2A. The 
Coomassie blue-stained SDS-PAGE profiles for the proteins at each step of the 
purification scheme are shown in Fig. 2.2B. 
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Figure 2.1 Rho-catalyzed nucleotide exchange activity of αT in various 
detergents. A. Tryptophan fluorescence emission profiles of Rho-catalyzed nucleotide 
exchange in maltoside detergents at a concentration of 2xcmc (HM: Hexyl Maltoside, 
NM: Nonyl Maltoside, DM: Decyl Maltoside, UM: Undecyl Maltoside, DDM: Dodecyl 
Maltoside), Inset: rate constants obtained from single exponential fits of the data (n=3). 
B. Tryptophan fluorescence emission profiles of Rho-catalyzed nucleotide exchange in 
maltose neopentyl glycol detergents at a concentration of 2xcmc (OMNG: Octyl Maltose 
Neopentyl Glycol, DMNG: Decyl Maltose Neopentyl Glycol, LMNG: Lauryl Maltose 
Neopentyl Glycol), Inset: rate constants obtained from single exponential fits of the data 
(n=3). C. Tryptophan fluorescence emission profiles of Rho-catalyzed nucleotide 
exchange in DDM at various detergent concentrations (cmc=0.0087% w/v). D. 
Tryptophan fluorescence emission profiles of Rho-catalyzed nucleotide exchange in 
LMNG at various detergent concentrations (cmc=0.001% w/v). 
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Figure 2.2  Purification of the Rho-GT complex.  A, Purification scheme.  B, SDS-
PAGE gel of the purification process (This is a representative of more than 20 repetitions 
of the purification process). 
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The complex was formed by first mixing αT, a chimeric protein comprised of an αT 
backbone with a stretch of residues from αi1, with β1γ1 in a 1:1:1 molar ratio.  
The αT subunit was expressed in E. coli with an N-terminal His6-tag and purified by Ni-
NTA chromatography followed by ion exchange and size exclusion chromatography. The 
β1γ1 complex was purifed from bovine retina. The resulting GT heterotrimer was then 
mixed with urea-washed bovine ROS membranes containing native Rho in its dark state. 
Because of the high-density of Rho in ROS, a significant amount of Rho may not be 
accessible to GT upon light-activation. Therefore, a substantial excess of Rho was used to 
assemble the Rho-GT complex (typically 7 Rho per GT). The mixture was subjected to 
illumination at 4ºC, resulting in the light-activation of Rho (Rho) and the induction of 
complex formation on the native ROS membranes. The mixture was then centrifuged 
and, as a result, the Rho-GT complex and excess Rho were in the pellet, whereas the GDP 
released during GT activation, together with the unbound αT subunit, remained in the 
supernatant. The pellet was solubilized with buffer containing the detergent LMNG and 
applied to a Ni-sepharose column. Due to the His6-tag present at the N-terminus of αT, 
the Rho-GT complex remained bound to the column and was thus separated from free 
Rho. The Rho-GT complex was eluted from the column with imidazole and further 
purified by size exclusion chromatography. The Rho-GT complex eluted as a single 
symmetrical peak (Fig. 2.3C). The yield of a typical purification process was about 80% 
based on the amount of β1γ1 complex used. 
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Figure 2.3  Stoichiometry determination and SEC profiles of the purified Rho-
GT complex A, UV-Vis spectrum of purified complex. (This is a representative of more 
than 20 similar specta of the purified complex) B, Rho:GT ratio determined by 
[35S]GTPγS binding assay and rhodopsin A380nm. (This experiment was repeated 3 times)  
C, SEC profiles of purified complex (red) and complex dissociation with the addition of 
GTPγS (green). (This is a representative of more than 10 similar sets of SEC profiles) D, 
SEC profiles of Day 1 (blue) and Day 7 (orange) complexes. (This is a representative of 
more than 20 similar sets of SEC profiles) 
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Stoichiometry, activity and stability of the Rho-GT complex 
Bovine Rho has been shown to form arrays of dimers in ROS membranes (17) and 
there have been questions raised regarding whether the stoichiometry between Rho and 
GT in the signaling complex is 1:1 or 2:1.  
The UV/Vis spectrum of the purified complex reveals two peaks at 280 nm and 380 
nm (Fig. 2.3A), corresponding to the absorbance of the protein moiety, and that of the 
unprotonated all-trans retinal in the meta-II Rho state, respectively. The A280nm/A380nm 
ratio is 3.7, which agrees with a 1:1 stoichiometry based on the reported extinction 
coefficients for the protein components (18-20) (a 2:1 stoichiometry would result in a 
A280nm/A380nm ratio of 2.58). 
Additionally, the stoichiometry between Rho and GT was determined with a radio-
nucleotide filter binding assay, in which the purified Rho-GT complex was incubated with 
[35S]GTPγS and then applied to a nitrocellulose filter. The amount of GT present in the 
complex was estimated based on its nucleotide binding capacity, i.e. the amount of bound 
[35S]GTPγS, and was compared with the amount of Rho calculated from the 380 nm 
absorbance. The result showed that for one mole of Rho, there was 0.784 ± 0.003 mole 
GTPγS present, supporting the idea of a 1:1 Rho-GT complex (Fig. 2.3B). 
The purified Rho-GT complex was fully active as it dissociated upon the addition of 
GTPγS, a non-hydrolysable analogue of GTP (Fig. 2.3C). The complex was stable at 4ºC 
in the dark for at least 7 days, as it remained nearly completely intact with less than 5% 
dissociation (Fig. 2.3D). 
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Figure 2.4  SAXS data and analyses of the Rho-GT complex.  A, SAXS data, 
curves from top to bottom are from 1, 0.5, 0.25 mg/mL respectively. (Each curve was the 
average of 10 scattering curves)  B, Guinier plots for q*Rg<1.3 region of the scattering 
curve.  C, Pair distribution function calculated from 1 mg/mL scattering profile. D, SAXS 
parameters and calculation results. 
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Small Angle X-ray Scattering (SAXS) analysis of Rho-GT  complex 
To further study the overall conformation of the active state of the Rho-GT complex, 
SAXS data were collected over a concentration range of the purified complex, with 
corrections for the background scattering being obtained by subtracting the scattering due 
to the SEC buffer from the scattering profiles of the Rho-GT samples (Fig. 2.4A). The 
Guinier regions (qRg<1.3) of these curves are linear (Fig. 2.4B), confirming that the Rho-
GT complex is monodisperse. All the parameters calculated from the SAXS scattering 
profiles are summarized in Fig. 2.4C. The radius of gyration (Rg) values for the Rho-GT 
complex calculated from the Guinier plots range from 41.7 to 43.9 Å, which agree well 
with those calculated from pair distribution functions (P(r)) using GNOM (21) (41.9 to 
43.9 Å). These results demonstrate that the value for Rg is concentration-independent. 
The molecular mass of the Rho-GT complex was calculated using both the particle mass 
determination method with ScÅtter software developed by Rambo et al. (22) and SAXS 
Mr developed by Fischer et al. (23). The results from ScÅtter (129.6 to 143.8 kD) and 
SAXS Mr (127.4 to 128.9 kD) agree well with each other and confirm that the complex is 
composed of 1 Rho and 1 GT, which gives a molecular mass value of 125 kD. The P(r) 
curve (Fig. 2.4D) calculated from GNOM is skewed to the right, indicating an elongated 
overall particle shape. The cross-sectional Rg (Rc) values calculated using ScÅtter 
software range from 32.5 to 34.9 Å, which are about 9 Å smaller than the Rg values, 
confirming the existence of an elongated shape for the Rho-GT complex. 
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FIGURE 2.5 Ab initio envelopes and model of the Rho-GT complex. A. DAMMIN 
envelopes (averaged and filtered envelopes are colored in grey and blue respectively). B. 
GASBOR envelope. C. Superimposition of complex model with GASBOR envelope. 
Rho is in red, GαT GTPase domain is in green, GαT helical domain is in yellow, Gβ1 is in 
cyan, Gγ1 is in grey, detergents are shown as orange beads. D. Theoretical scattering 
profile of the model (red line) overlain with experimental data (grey dots) E. Position of 
GαT helical domain (gold) in the model compared with open (purple) and close (blue) 
positions from crystal structures.  
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SAXS-based modeling of Rho-GT complex 
The P(r) curve (Dmax=128 Å) calculated from the scattering profile for the 1 
mg/mL Rho-GT sample was used for generating ab initio models of the complex. Two 
different algorithms, DAMMIN (24) and GASBOR (25), were used. The resulting 
envelopes obtained using each method agree well with each other. Both revealed a small 
bulge protruding out from the bottom half of the envelopes, indicating the position of the 
helical domain of αT (Figs. 5A and 5B). A structural model of the Rho-GT complex, 
using the crystal structure of the β2AR-GS complex (PDB 3SN6) as a template, was 
generated to fit the envelopes. There is significant discrepancy between the structural 
model and ab initio envelopes at the Rho region, which can be attributed to the existence 
of a detergent micelle around the receptor in solution and, as a result, the model fits 
poorly to the experimental data with χ2=24.2. In order to improve the quality of the 
structural model, a detergent corona shaped as an elliptical torus was built around Rho 
using the Memprot program developed by Pérez et al. (26). The resulting micelle model 
is composed of 78 LMNG detergent tails and 74 detergent heads, and its dimensions are 
shown in Fig. 2.5C. After incorporating the detergent corona into the complex model, the 
χ2 value decreased to 3.27, indicating a significant improvement of fitness to the 
experimental data. In addition, the position of the helical domain was further optimized 
with the program CORAL (26) and the χ2 value of the model improved to 1.83 (Fig. 2.5D 
and E). The helical domain position in the resulting model resides between the close and 
open positions as indicated from X-ray crystal structures (PDB 1GOT and 3SN6 
respectively) (Fig. 2.5E). 
 
	 53	
 
 
 
 
 
 
 
 
 
Figure 2.6  2D projection analysis of the Rho-GT complex.  A, Raw EM image of 
detergent solubilized Rho-GT complex embedded in negative stain.  B, Representative 
EM class averages of the Rho-GT complex (positions of αΤ helical domain indicated by 
arrow). The cartoon model represents the conformations reflected by the EM averages, 
depicting the variable positioning of the helical domain (the position of the detergent 
micelle is indicated by gray shaded arcs and labeled with “m”). 
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Electron microscopy characterization of negatively stained Rho-GTcomplex 
EM visualization of the negatively stained complex samples showed a 
monodisperse particle population (Fig. 2.6A). Reference-free alignment and classification 
of particle projections revealed class averages with an overall density similar to that of 
the β2 adrenergic receptor-GS protein complex (β2AR-GS) (14) (Fig. 2.6B). A central oval 
density represents Rho in a detergent micelle with a small protruding density often 
observed on top corresponding to the N-terminus of Rho. At the bottom of Rho, two 
major densities representing the GT heterotrimer are clearly visible. One of the two 
densities has extensive contact with the receptor density and shows an additional small 
globular density in various orientations in several class average images. This is similar to 
what was observed for the β2AR-GS complex (14) and represents the Ras-like domain of 
the αT subunit, with a flexible helical domain in the Rho-GT complex. The other density 
therefore corresponds to β1γ1.  
 
DISCUSSION 
Structural information obtained from a variety of approaches will be invaluable in 
shedding light on how the photoreceptor Rho engages and activates its signaling partner, 
the G protein GT.  Such analyses will also provide insights with broad relevance toward 
understanding the underlying mechanisms by which GPCRs demonstrate remarkable 
specifity for their G protein targets, as well as whether different GPCRs use common or 
distinct mechanisms in catalyzing the G protein activation event. Recently, there have 
been several reports of the purification of detergent-solubilized Rho-GT complexes, in 
which either native (28,29) or recombinant Rho (30,31) was utilized. Our approach 
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toward obtaining an active Rho-G protein complex differs from these previous efforts in 
two major aspects. First, rather than detergent-solubilizing and purifying Rho prior to 
allowing it to associate with a purified G protein, the Rho-G protein complex was 
obtained by directly light-activating the urea-washed ROS membranes in the presence of 
the heterotrimeric, chimeric G protein GT. This allowed the formation of a Rho-GT 
complex within a native membrane environment. The subsequent pelleting step readily 
removed the released GDP, which may otherwise destabilize the complex. Secondly, 
instead of using either the glycan linkages or C-terminus of Rho as purification handles, 
we utilized the N-terminal His-tag on the recombinant αT subunit to achieve a simple and 
efficient one-step purification of the detergent-solubilized Rho-GT complex. The 
resulting complex dissociated with the addition of GTPγS, demonstrating that the 
complex isolated in this manner is fully active.  
Near-infrared light scattering studies of ROS membranes in the early 1980’s by Kuhn 
and colleagues suggested a 1:1 stoichiometric association of GT with Rho (32). However, 
atomic force microscopy images of ROS membranes revealed that Rho exists in the form 
of dimeric arrays in its native environment (17). Recent studies using native rhodopsin 
solubilized from ROS with detergent for complex formation (28,29) argued for the 
existence of a pentameric complex consisting of two Rho molecules and one GT 
heterotrimer as the minimal functioning unit.  While in these settings, it may appear that 
Rho can form dimers, the important question is what stoichiometry of Rho and GT is 
required to achieve full activation. Based on our studies of a signaling active Rho-GT 
complex, as analyzed by UV/Vis spectroscopy and radioactive nucleotide binding, as 
well as by SAXS and EM, we conclude that the minimal unit necessary for full activation 
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is 1 Rho and 1 G protein.  This conclusion is supported by recent studies using rhodopsin 
embeded nanodiscs which have shown that one Rho is sufficient for coupling to and 
activating GT (33-34). Moreover, based on nanodisc reconstitution, monomeric rhodopsin 
has been shown to be sufficient for phosphorylation by G protein-coupled receptor kinase 
(GRK) and interaction with arrestin (35-36). And the recent X-ray crystallography 
structure of a rhodopsin-arrestin complex (37), have futher illustrated that rhodopsin 
binds arrestin in a 1:1 stoichiometry. Similarly, β2- adrenergic receptor has been 
demonstrated to interact with Gs in a monomeric manner (6, 14, 38). Therefore several 
lines of evidence now point to class A GPCR monomers being sufficient for promoting 
their downstream signals. 
In addition to the limit stoichiometry necessary to achieve a signaling-active complex, 
another question of interest is the positioning of the helical domain of the Gα subunit in 
the receptor-G protein complex. The first high-resolution structure of a G protein α 
subunit, that for GTPγS-bound αT (39), revealed that the nucleotide is buried inside a 
cleft formed by the Ras-like domain and helical domain, and it was postulated that an 
activated receptor must induce an opening of the cleft in order to allow for nucleotide 
exchange. The first direct evidence of this inter-domain opening was provided by double 
electron-electron resonance (DEER) experiments (40), in which distance increases as 
large as 20 Å between the Ras-like and helical domains of the Giα subunit were observed 
upon binding to light-activated ROS. The crystal structure of the β2AR-GS complex (6) 
shows a very dramatic 127° rotation of the GSα helical domain, which results in the 
opening of the nucleotide-binding pocket. Our SAXS model of the Rho-GT complex 
shows that the helical domain of αT adopts a similar open position in solution. However, 
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the opening is not as dramatic as displayed in the β2AR-GS complex crystal structure. 
Negative stain electron microscopy (EM) studies of the β2AR-GS complex (14) reveal the 
flexible positioning of the GSα helical domain and suggest an ensemble of open helical 
domain positions which exist under physiological conditions. Since a similarly flexible 
helical domain is also observed in the negative-stain EM images of the Rho-GT complex, 
it is most likely that a displacement of the helical domain is a universal mechanism of 
receptor-mediated nucleotide exchange for different families of heterotrimeric G proteins.  
In conclusion, here we describe procedures for isolating a Rho-G protein complex 
with very high yield that is amenable to a variety of types of biochemical and structural 
analyses.  Given the availability of a number of interesting mutants of αT, which mimic 
different stages in the activation event, we should soon be in position to address 
fundamentally important questions regarding how different members of the GPCR family 
engage their G protein signaling partners and induce the necessary structural changes to 
drive G protein-mediated signal propagation.  
 
METHODS 
Materials 
Frozen dark-adapted bovine retinae were purchased from W.L. Lawson Co. (Lincoln, 
NE). Detergents were from Anatrace and all other chemicals were obtained from Sigma-
Alrich. 
Purification of retinal proteins 
Urea-washed rod outer segment (UROS) membranes were isolated as described (41), 
flash-frozen and stored at −80°C in HMN buffer (20 mM HEPES, pH 7.5, 2 mM MgCl2, 
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100 mM NaCl, 1 mM DTT) at a concentration of 300 µΜ. UROS membranes were used 
as the source for Rho in Rho-GT complex formation. The β1γ1 subunit complex was 
purified essentially as described previously (42). Bovine retinae were exposed to light 
and subjected to sucrose gradient ultra-centrifugation to prepare purified rod outer 
segment (ROS) membranes. After a series of isotonic and hypotonic washes, 100 µΜ 
GTP was added to release GT subunits from the membrane. β1γ1 was separated from αT 
through a 5 mL HiTrap Blue HP (GE Healthcare) column and the resulting β1γ1 complex 
was further purified by anion exchange chromatography through a 5 mL HiTrap Q HP 
(GE Healthcare) column, using Buffer A (20 mM HEPES, pH 7.5, 2 mM MgCl2, 1 mM 
DTT, 10% glycerol) and Buffer B (Buffer A + 1 M NaCl) to form the gradient. The β1γ1 
complex typically elutes at 100 mM NaCl and was concentrated to 20 µM, flash-frozen 
and stored at –80°C.  
Expression and purification of αT 
An αT/αi1 chimeric construct designated as pHis6Chi8 was obtained from Dr. Heidi 
Hamm (Vanderbilt University) (43), in which αT residues 215 to 295 were replaced with 
the corresponding residues from αi1 and a His6 tag was introduced at the N terminus. In 
addition, residues 244 and 247 were changed back to the original amino acids in αT, 
resulting in the αT construct. The αT subunit can undergo Rho-catalyzed nucleotide 
exchange and activate the effector enzyme, PDE, in a similar manner as retinal αT. αT 
was expressed in BL21(DE3) competent cells and purified as described previously (18). 
The protein was concentrated to 20 µM in HMN buffer with the addition of 10% 
glycerol, flash-frozen and stored at −80°C. 
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Detergent selection for Rho-GT complex purification 
Fluorescence measurements were carried out with a Varian eclipse 
spectrofluorimeter. UROS was light activated (Rho) by incubation on ice under ambient 
light for 5 min. Rho-catalyzed nucleotide exchange on the αT subunit in detergents was 
monitored by premixing 5 nM Rho and 300 nM β1γ1 in HMN buffer with 50 µM GTPγS 
and different detergents at various concentrations, monitoring tryptophan fluorescence 
(excitation: 300 nm; emission: 345 nm) in real-time upon the addition of 300 nM αT. All 
kinetic traces were corrected for the fluorescence from Rho and β1γ1, and the data were 
fitted to a single exponential equation: ! = !! − (!! − !!) ∙ !!!!"#∙! 
where F is the fluorescence signal at any time t, !! is the fluorescence signal at time ! = 0, !! is the fluorescence signal at time ! = ∞, and !!"# is the observed rate constant. 
 
Rhodopsin-GT complex formation and purification 
The G protein heterotrimer GT was formed by mixing 22 nmol of αT with 20 nmol 
β1γ1, and then incubated on ice for 5 minutes. The Rho-GT complex was formed on ROS 
membranes by mixing GT with UROS containing 140 nmol Rho and illuminating the 
mixture under a halogen lamp covered with a UV-absorbing glass and a 495 nm long-
pass filter at 4°C for 30 min. The suspension was aliquoted into 1.5 mL eppendorf tubes 
and centrifuged at 14,000g for 30 min. From here on, all subsequent steps were carried 
out in the dark under dim red light. The supernatant was disgarded and the pellets 
containing the Rho-GT complex and excess Rho were resuspended in 3 mL HMN buffer 
+ 1% (w/v) LMNG. The mixture was incubated at 4°C with rocking for 30 min to allow 
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for complete solubilization. HMN buffer (12 mL) was then added to lower the LMNG 
concentration to 0.2% and the sample was further incubated at 4°C with rocking for 1 
hour. Solubilized complex was loaded onto a 1 mL HisTrap FF column (GE Healthcare) 
pre-equilibrated with HMN buffer + 0.02% LMNG. The Rho-GT complex was eluted 
from the column with an imidazole gradient in HMN buffer + 0.02% LMNG, as a single 
peak at ~100 mM imidazole. Peak fractions were pooled and concentrated with an 
Amicon Ultra-0.5 100 kD MWCO concentrator (EMD Millipore) to 500 µL and injected 
onto a Superdex 200 10/300 GL column (GE Healthcare), pre-equilibrated with HMN 
buffer + 0.02% LMNG. Peak fractions were pooled and concentrated with an Amicon 
Ultra-0.5 100 kD MWCO concentrator (EMD Millipore) to 50 µL, resulting in a complex 
concentration of ~40 mg/mL. 
Determination of the stoichiometry of the Rho-GT complex 
The stoichiometry of Rho and GT within the complex was determined using two 
methods, UV/Vis absorption spectroscopy and a [35S]GTPγS binding assay. For 
stoichiometry determinations using UV/Vis spectroscopy, a 100 µL sample of the 
purified Rho-GT complex was examined in a quartz cuvette with a 1 cm path length, 
using a Beckman DU600 UV/Vis spectrophotometer scanning from 240 nm to 700 nm at 
240 nm/min. The ratio for Rho to GT within the complex was determined from the 
A280nm/A380nm ratio, using the following extinction coefficients: Rho (ε280nm = 61,800 M-
1cm-1, ε380nm = 42,000 M-1cm-1) (19, 20), αT (ε280nm = 35,870 M-1cm-1), and β1γ1 (ε280nm = 
57,400 M-1cm-1). The extinction coefficients for αT and β1γ1 were calculated based on 
protein sequence using the ExPASy ProParam tool (44). Therefore, a 1:1 Rho:GT 
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stoichiometry would result in an A280nm/A380nm value of 3.69, whereas a 2:1 Rho:GT 
stoichiometry would yield a A280nm/A380nm value of 2.58. 
For stoichiometry determinations using a [35S]GTPγS binding assay, purified Rho-GT 
complex was incubated with 50 µM [35S]GTPγS for 10 minutes on ice in 20 µL HMN 
buffer + 0.003% LMNG. The solution was then applied to prewet nitrocellulose filters 
(Schleicher & Schuell, pore size 0.45 µm) on a suction manifold. The filters were washed 
twice with HMN buffer and added to scintillation liquid (30% LSC Scintisafe Mixture) 
and counted in a scintillation counter (LS6500 multipurpose scintillation counter). The 
calculated amount of bound [35S]GTPγS was used as an estimate for the amount of GT in 
the complex and was compared with the amount of Rho calculated from A380nm, using the 
extinction coefficient of Meta II rhodopsin, ε380nm = 42,000 M-1cm-1. 
SAXS data collection and processing 
SAXS data was collected at the G1 station of the Cornell High Energy Synchrotron 
Source (CHESS). G1 operated with an energy of 9.86 keV and provided a flux of 3×1011 
photons/sec for a 250×250 µm beam. Purified Rho-GT complex was eluted through a 
Superdex 200 5/150 GL column (GE Healthcare), pre-equilibrated with HMN buffer 
without detergent, immediately prior to the collection of SAXS data. The center peak 
fraction was collected and a concentration series, 0.25, 0.5 and 1 mg/mL, was prepared in 
HMN buffer and kept on ice. Samples were centrifuged at 14,000g for 10 minutes before 
being loaded into the SAXS sample exposure window. Samples were exposed for 30 
seconds with oscillation. Ten datasets were collected for each sample for possible 
radiation damage detection and undamaged exposures were averaged. Buffer 
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measurements with HMN buffer were conducted in-between each sample measurement. 
Data reduction and background subtraction were done with RAW data reduction software 
(45). The program ScÅtter (22) was used to obtain the Guinier plot and calculate the 
radius of gyration (Rg) and I(0) values. Particle distance distribution P(r) was calculated 
using GNOM (20). 
SAXS-based modeling of the Rho-GT complex 
Ab initio models were calculated using two different programs, DAMMIN (24) and 
GASBOR (25). In DAMMIN calculations, 17 envelopes were generated (average 
χ2=0.90) and the results were averaged using DAMAVER (46) to produce the averaged 
and filtered envelopes. None of the 17 DAMMIN envelopes was rejected during the 
DAMAVER calculation and the mean normalized special discrepancy value (NSD) was 
0.482 ± 0.053, indicating the model is of good quality. In addition to DAMMIN, 
GASBOR calculations were performed to fit the intensity in reciprocal space. The 
resulting envelope fits well to the experimental curve with χ2=0.895. A structural model 
was built using the X-ray crystal structure of the β2AR-GS complex (3SN6) as a template. 
In this model, the X-ray crystal structures of meta-rhodopsin II (PDB 3PXO), and the 
β1γ1 complex from the GT heterotrimer (PDB 1GOT), were used for Rho and β1γ1 
respectively. A homology model of the αT subunit was built based on the αS subunit from 
the X-ray crystal structure of the β2AR-GS complex (PDB 3SN6) using the SWISS-
MODEL server (44). The program Memprot (26) was used to model the LMNG 
detergent micelle around Rho, in which a coarse-grained fitting algorithm was used to 
add detergent molecules by assuming an elliptical model for the detergent corona.  
Electron density values of 0.28 and 0.52 e·Å-3 were used for the hydrophobic and 
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hydrophilic portions of the LMNG detergent molecule, respectively. The position of the 
helical domain (residues 57-176 in αT) was optimized using the program CORAL (27), in 
which the linker regions (residues 51-56 and 177-181) connecting the helical domain to 
the GTPase domain were set to be random flexible loops. The resulting structural model 
was aligned with the envelopes using the SUPCOMB (47) program. 
 
Specimen preparation and EM imaging of negative-stained samples 
Purified Rho-GT complex was prepared for electron microscopy using the 
conventional negative staining protocol (48), and imaged at room temperature with a 
Tecnai T12 electron microscope operated at 120 kV, using low-dose procedures. Images 
were recorded at a magnification of ×71,138 and a defocus value of ~1.5 µm on a Gatan 
US4000 CCD camera.  
Two-dimensional classifications of the Rho-GT complex 
All images were binned (2 pixels × 2 pixels) to obtain a pixel size of 4.16 Å on 
the specimen level. Particles were manually excised using e2boxer (49) (part of the 
EMAN2 software suite). Two-dimensional reference-free alignment and classification of 
particle projections were performed using ISAC (50). A total of 9,303 projections of 
Rho-GT were subjected to ISAC, producing 134 classes consistent over two-way 
matching and accounting for 6,774 particle projections. 
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Chapter 3 
* 
Cryo-EM Structure of the Rhodopsin-Transducin Complex 
 
 
INTRODUCTION 
Rhodopsin (Rho), the photoreceptor evolved for scotopic vision in vertebrates, is 
a prototypical member of the G protein-coupled receptor (GPCR) family, which is the 
largest family of membrane proteins in mammalian cells with over 800 members1. 
GPCRs share a common structural motif of seven transmembrane helices and are 
responsible for transmitting signals triggered by a wide variety of extracellular stimuli, 
including photons, odorants, hormones and neurotransmitters, across the cell membrane. 
These signals are transmitted through the activation of heterotrimeric G proteins (Gαβγ), 
with the active state being defined as the complex between agonist-bound receptor and 
nucleotide-free G protein2. In contrast to the vast diversity of GPCRs, there are only a 
relatively small number of G proteins, which are categorized based on the sequence 
similarity shared between their α subunits into four classes: GS, Gi, Gq and G123. In the 
visual phototransduction pathway4, the GPCR Rho is composed of the apoprotein opsin 
and a covalently bound ligand 11-cis retinal which acts as an inverse agonist for the 
receptor. The absorption of a photon induces the cis-trans isomerization of retinal, 
generating a ‘full agonist’ capable of activating the receptor. Activated Rho can then 
recruit transducin (GT, its subunits are designated as GαT, Gβ1, Gγ1), a member of the Gi 
family of heterotrimeric G proteins, and catalyze the exchange of GDP for GTP within 																																																								
Cryo-EM data acquisition, image processing and 3D reconstructions were contributed by our collaborator 
Dr. Georgios Skiniotis and his lab member Dr. Hongli Hu at Stanford University.	
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the GαT subunit. GTP-bound GαT then binds and activates the effector enzyme, the 
cGMP phosphodiesterase (PDE6), which reduces the cytosolic concentration of the 
second messenger cGMP. The abundance of Rho in vertebrate retinae5 and its relatively 
high stability make it an attractive model system for studying GPCR structural 
mechanisms. Crystallization efforts on Rho have yielded the first high-resolution 
structure of a GPCR in its inactive state6, and subsequently, structures of the apoprotein 
opsin7,8 and all-trans retinal-bound Rho9. In the past decade, with the development of 
techniques such as T4 lysozyme fusion10,11, thermostabilizing mutagenesis12,13 and in 
meso crystallization14, the number of GPCR structures has increased dramatically, such 
that currently there are more than 200 high-resolution structures of GPCRs for over 40 
different receptors15. However, only a small fraction of these structures are of activated 
receptors, and despite the tour de force achievement of the active-state β2-adrenergic 
receptor-GS protein complex (β2AR-GS) structure by Kobilka and colleagues in 201116, 
GPCR-G protein complexes have been generally unyielding to X-ray crystallography 
efforts.  
Most recently, with the advent of direct electron detectors17 and beam-induced 
motion correction softwares18,19, single-particle cryo-electron microscopy (cryo-EM) has 
emerged as a powerful tool for high-resolution structural determination without the need 
for extensive protein engineering and crystallization. During the past year, cryo-EM has 
been used to obtain three structures of two different GPCRs, namely the calcitonin 
receptor20 and the glucogon-like peptide-1 (GLP-1) receptor21,22, coupled to the GS 
protein. The available GPCR-G protein complex structures have yielded valuable 
structural information about the mechanisms of receptor activation and the interaction 
	 74	
between agonist-bound receptors and heterotrimeric G proteins. Moreover, they have 
illustrated how diverse GPCRs share topological similarities on their cytoplasmic regions 
and engage the same GS protein. Despite this progress, the details underlying the 
observed specificity between GPCRs and their specific signaling partners from different 
G protein classes have for the most part remained elusive. The recent cryo-EM structures 
of µ-opioid receptor23 and Rho24 coupled to the inhibitory Gi protein have begun to 
address this question, revealing how Gi engages GPCRs in a different orientation than GS. 
In order to further our understanding of GPCR-G protein coupling specificity, and to 
learn more about the mechanisms by which GPCRs activate their specific G protein 
partners, we have obtained a near-atomic resolution cryo-EM structure of the 126 kD 
complex between light-activated, native bovine Rho and its cognate G protein partner 
transducin.  Analysis of this complex shows how a Gi-like G protein transducin engages 
an activated GPCR in a manner distinct from the interactions of GPCRs with the GS 
protein, as well as reveals the diverse modes of coupling between GPCRs and different G 
proteins within the same inhibitory family.  Moreover, this cryo-EM structure highlights 
the unique aspects regarding how light-activated Rho catalyzes GDP-GTP exchange on 
the GαT subunit.  
 
RESULTS 
Isolation of a stable rhodopsin-transducin complex 
The active-state Rho-GT complex was formed with Rho and the G protein β1γ1 
complex purified from bovine retinae, and a recombinant transducin α subunit in which 
18 residues of bovine GαT are replaced with corresponding residues from Gαi125; (from 
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here on referred to simply as GαT).  The addition of Gαi1 residues allowed GαT to be 
expressed and purified in E coli, and a His6-tag was introduced at its N-terminus to serve 
as a purification handle for subsequent extraction of the Rho-GT complex from purified 
bovine rod outer segments (ROS)26.  Recombinant GαT can undergo Rho catalyzed GDP-
GTP exchange and activate the downstream effector PDE6 as effectively as bovine 
GαT27,28 and significantly better than Gi, which is poorly activated by Rho and is 
incapable of activating PDE6.  
In order to form the Rho-GαT-β1γ1 (Rho-GT) complex, purified bovine ROS 
membranes containing native dark-state Rho was initially mixed with GαT and native 
bovine β1γ1 in the dark. The mixture was then illuminated with white light, resulting in 
the activation of Rho and the ensuing formation of the complex on the ROS membranes. 
The active-state complex was then extracted with the detergent lauryl maltose neopentyl 
glycol (LMNG)29 and purified with Ni-immobilized-metal affinity and size exclusion 
chromatography. The Rho-GT complex is stable at 4 °C in the dark for over a week and is 
fully active, as it readily dissociates upon the addition of GTPγS, a non-hydrolysable 
GTP analogue26. The monodispersity of the complex was confirmed with negative-stain 
EM and single-particle two-dimensional (2D) averaging30. 
 
Cryo-EM structure determination of the Rho-GT complex 
We utilized single-particle cryo EM to determine a high-resolution structure of 
the light-activated Rho-GT complex without the addition of a nanobody or antibody 
fragment. Cryo-EM micrographs revealed monodispersed complex particles and 2D 
classification of the particles unveiled complex projections with clear secondary 
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structural features, including the transmembrane helix bundle of Rho embedded in a 
detergent micelle and all three subunits of GT. Subsequent 3D reconstruction yielded a 
density map that accomodates a 1:1 complex consisting of monomeric Rho and GT. 
Interestingly, there is a visible density for the helical domain of GαT in the low resolution 
map (Fig. 3.1a), suggesting that this domain in nucleotide-free GαT is more rigid 
compared to the helical domain in the β2AR-GS complex31. However, the helical domain 
within GαT is still significantly more flexible compared to the other components making 
up the Rho-GT complex. Therefore, in order to improve the resolution, densities for the 
helical domain and the detergent micelle were subtracted out. Refinement in 3D yielded a 
cryo-EM density map of the Rho-GT complex with an indicated nominal global 
resolution of 4.5 Å (Fig. 3.1b). The quality of the cryo-EM map is highest in the receptor 
region and receptor-G protein interface. A near-atomic resolution structure of the Rho-GT 
complex without the helical domain was built into the map (Fig. 3.1c) and allowed us for 
the first time to directly visualize how the photoreceptor specifically engages and 
activates its cognate signaling partner GT. 
 
Structure of the active-state rhodopsin 
The first high-resolution GPCR structure solved by X-ray crystallography was 
obtained for Rho in its dark (inactive) state.  Subsequently, a series of structures for Rho 
in its various signalling states were determined, namely, the apo protein opsin7, the 
agonist-bound meta II state9, meta II Rho bound to the GαT C-terminal peptide (GαTCT)9, 
and the Rho-arrestin complex32.  
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Figure 3.1 Cryo-EM structure of the rhodopsin-transducin complex. a, low-
resolution cryo-EM map showing the density of the α helical domain. b, orthogonal 
views of the refined cryo-EM density map. c, structure of the rhodopsin-transducin 
complex colored by subunit shown in the same views. Rho: red, GαT: green, Gβ1: cyan, 
Gγ1: magenta. 
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In comparison to the inactive Rho structure, the most significant changes in the structure 
for GT-bound light-activated Rho reported here are in the intracellular loop 3 (ICL3) 
region, which in dark-state Rho is a 15-residue-long extended loop. The N-terminal 10 
residues of ICL3 fold into an α-helix forming a 15 Å downward extension of 
transmembrane helix 5 (TM5), with the shortening of ICL3 pulling TM6 outward by 7 Å. 
In addition, there are also subtle outward movements in ICL1 and ICL2, as well as in the 
cytoplasmic ends of TM1 and TM4, and a 13° horizontal rotation of helix 8 (H8). These 
concerted movements open up the cytoplasmic cavity of Rho and provide a binding 
interface to engage GαT (Fig. 3.2a). The overall architecture of Rho in the Rho-GT 
complex is similar to structures for GαTCT-bound Rho9 (root mean squre deviation 
(RMSD) of 1.13 Å) (Fig. 3.2b) and the arrestin-bound Rho30 complex (RMSD of 1.15 Å) 
(Fig. 3.2c). Residues in the highly conserved E(D)RY and NPxxY motifs of Rho, which 
are important for GPCR activation, adopt similar conformations in all three structures 
(Fig. 3.2d, e). There are subtle changes in the Rho-GT structure compared to that for 
GαTCT-bound Rho, specifically, a 2.6 Å outward movement of ICL3 and a 1.7 Å 
downward movement of H8, allowing the receptor to better engage the full length G 
protein. Comparisons with the arrestin-bound Rho structure show a notable difference in 
ICL2, which moves 7.5 Å inward and forms an α helix while engaging arrestin. The ICL2 
helix narrows the cytoplasmic cavity of the receptor preventing it from fully 
accommodating the larger signaling partner, the G protein, and could be a significant 
structural feature utilized by activated Rho to differentially interact with GT versus 
arrestin. 
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Figure 3.2 Structural comparison between the transducin-bound rhodopsin and 
rhodopsin in various signaling states. a, orthogonal views of the superimposition 
between the GT-bound (red) and inactive (magenta, PDB 1U19) rhodopsin. b, orthogonal 
views of the superimposition between the GT-bound (red) and GαTCT-bound (green, PDB 
3PQR) rhodopsin. c, orthogonal views of the superimposition between the GT-bound 
(red) and arrestin-bound (yellow, PDB 5W0P) rhodopsin. d, comparison of residues from 
the conserved E(D)RY and NPxxY motifs in the GT-bound and GαTCT-bound rhodopsin 
structures. e, comparison of residues from the conserved E(D)RY and NPxxY motifs in 
the GT-bound and arrestin-bound rhodopsin structures.  
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The Rho-GT interface: insights into G protein-coupling specificity 
In the Rho-GT complex structure, Rho engages GT through the GαT subunit. This 
interaction is mainly mediated by extensive contacts between the cytoplasmic surface of 
Rho and the C-terminal α5 helix of GαT, together with an additional interaction between 
the ICL2 of Rho and the αN-β1 juncture of GαT. The overall architecture of the Rho-GT 
complex shows significant differences when compared to the β2AR-GS complex.16 The 
most notable difference in the receptor region is the orientation of TM6, which adopts a 
more closed conformation and moves inward by 10 Å in Rho (Fig. 3.3a). As a result of 
the distinct opening of TM6, GαT engages Rho in a markedly different orientation 
compared to how Gαs binds to the β2-adrenergic receptor. The α5 helix in GαT rotates 
away by 24° towards H8 in order to avoid clashing with the more inward-facing TM6 in 
Rho (Fig. 3.3a). This rotation propagates through the entire Ras-like domain of GαT and 
results in a 21° rotation of the αN helix, leading to a 19 Å rigid body movement of the 
Gβγ subunits (Fig. 3.3b), giving rise to an orientation of the G protein that is similar to 
what has been observed in the recent Rho-Gi protein complex (Rho-Gi) structure24, and as 
was reported in an electron paramagnetic resonance (EPR) study of the Rho-Gi 
complex33. The cytoplasmic positions of the receptor TM bundle in Rho-GT are very 
similar to those in the recent µ-opioid receptor-Gi protein complex (µOR-Gi) structure23 
(Fig. 3.3c), suggesting that this smaller outward tilt of TM6 may be a common feature 
utilized by GPCRs activating the Gi-family G proteins. However, the ICL3 of µOR 
differs from that in Rho as it is extended at the N-terminal end through the unwinding of 
the last helical turn of TM5, resulting in an inward movement by about 10 Å (Fig. 3.3c).  
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Figure 3.3 Different G protein orientations in Rho-GT complex, β2AR-GS complex 
and µOR-Gi complex. a, different Gα Ras domain α5 helix orientations in Rho-GT 
complex and β2AR-GS complex (PDB 3SN6). Rho: red, GαT: green, β2AR: orange, GS: 
yellow. b, different  G protein orientations in Rho-GT complex and β2AR-GS complex. c, 
different Gα Ras domain α5 helix orientations in Rho-GT complex and µOR-Gi complex 
(PDB 6DDF). Rho: red, GαT: green, µOR: cyan, Gi: magenta. d, different  G protein 
orientations in Rho-GT complex and µOR-Gi complex. 
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Consequently, although the α5 helix in µOR-Gi terminates at nearly the same position as 
it does in the Rho-GT complex, it tilts by 14° towards ICL2 as it exits the receptor, 
avoiding potential clashes with the more inward-facing ICL3 (Fig. 3.3c). As a result, the 
αN helix in Gi rotates by 23°, back to a similar receptor-coupling orientation adopted by 
GS (Fig. 3.3d).   
The α5 helix of GαT inserts as a straight α helix into Rho, terminated by a 4-
residue loop. The position of the C terminus (CT) of α5 agrees well with that of the GαT 
peptide in the structure for the GαTCT-bound Rho and is in close proximity to H8 (Fig. 
3.4a). However, this is different from the position of the α5 CT in the recent Rho-Gi 
structure, in which it shifts slightly downward out of the receptor (Fig. 3.4b). The closer 
proximity between the α5 CT of GαT and Rho likely reflects the better coupling of Rho 
with GT compared to its interaction with Gi. In the Rho-GT complex, the α5 CT slightly 
kinks at the second helical turn and tilts by 5° toward to directly engaging H8 (Fig. 3.4a). 
The main-chain carbonyl groups of residues 346-DCGL-349 (H5.22-H5.25, common Gα 
numbering (CGN) system34) at the end of the α5 CT form a negatively charged surface 
that undergoes electrostatic interactions with the positive charges of the main-chain 
amino groups at the N terminus of H8 (Fig. 3.4c). This interaction is strengthened by 
extensive hydrogen bonding with Rho residues R1353.50 (superscript indicating 
Ballesteros–Weinstein numbering for GPCRs35) from TM3, E2496.32 from TM6, together 
with K3118.48 and Q3128.49 from H8 (Fig 4d). This network of charge interactions is also 
present, though to a lesser extent, in the µOR-Gi complex (Fig. 3.4e).  
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Figure 3.4 Comparison of the interactions between Gα C terminus and receptor in 
Rho complexes, µOR-Gi complex and β2AR-GS complex. a, comparison of GαT C 
terminus orientation in Rho-GT and Rho-GαTCT (PDB 3PQR) complexes. Rho: red, GT: 
green, Rho-GαTCT: pink. b, comparison of GαT C terminus orientation in Rho-GT and 
Rho-Gi (PDB 3PQR) complexes. Rho: red, GT: green, Rho-Gi: grey. c, electrostatic 
interaction between backbone carbonyl (red spheres) of GαT C terminus and backbone 
amino groups (blue spheres) of helix 8 N terminus. d, interactions between GαT C 
terminus and Rho. e, interactions between Gαi C terminus (magenta) and µOR (purple). f, 
interactions between GαS C terminus (yellow) and β2AR (orange). 
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Whereas in the β2AR-GS complex, it is replaced by hydrophobic interactions, as GαS 
positions the H5.23-H5.26 tilt into the cavity formed by the more open TM6 and interacts 
with a large hydrophobic patch formed by TM5 (Fig. 3.4f). This significantly different 
mode of interaction provides a structural basis underscoring the importance of the α5 CT 
in determining G protein-coupling specificity36. Notably, despite the markedly different 
α5 CT positions, the backbone carbonyl of C347 (H5.22) in GαT (C351 in Gαi) adopts an 
almost identical position as the side-chain hydroxyl of Y391 (H5.22) and forms a 
hydrogen-bonding network with R1353.50 from the conserved E(D)RY motif and Y2235.58 
in the Y(x)7K(R) motif in TM5 (Fig. 3.4d,e,f), stablizing the receptor active-state 
conformation.  
Following the C terminal polar interactions with Rho, the GT α5 helix forms 
hydrophobic contacts through L344 (H5.20) and I340 (H5.16) with a hydrophobic patch 
at the interface between TM3 (V1393.54) and TM5 (T2295.64, V2305.65, A2335.68) (Fig. 
3.5a). Similar hydrophobic interactions also exist in µOR-Gi, but are more extensive with 
further contribution from nonpolar residues in ICL3 (Fig. 3.5b). In β2AR-GS however, the 
corresponding residue at H5.16 position is Q384 and it forms polar interactions with 
β2AR instead (Fig. 3.5c). As the α5 helix of GαT exits Rho, it interacts with ICL3 through 
a network of polar interactions, involving T2426.25 and Q2375.72 from Rho, and K341 
(H5.17), D337 (H5.13) from the α5 helix and Y316 (S6.2) from β6 strand of GαT (Fig. 
3.5a). Mutating any of the corresponding residues in Gαi to alanine would significantly 
impair complex formation with Rho37, suggesting the importance of this polar network in 
stabilizing the nucleotide-free complex.  
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Figure 3.5 Comparison of receptor-G protein interfaces in Rho-GT, µOR-Gi and 
β2AR-GS complexes. a, Interactions between GT α5 helix and Rho. Rho: red, GT: green. 
b, Interactions between Gi α5 helix and µOR. Gi: magenta, µOR: cyan. c, Interactions 
between GS α5 helix and β2AR. GS: yellow, β2AR: orange. d, Interactions between Rho 
ICL2 and GT. e, Interactions between µOR ICL2 and Gi. f, Interactions between β2AR 
ICL2 and GS. 
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This interaction network is not observed in the β2AR-GS structure (Fig. 3.5c) and is 
different from the mixed polar and nonpolar interactions that occur between the ICL3 of 
µOR and Gαi (Fig. 3.5 b). 
A second interaction site between Rho and GT involves ICL2 (Fig. 3.5d). Unlike 
the cases for the µOR and the β2AR (Fig. 3.5e,f), the ICL2 in Rho does not form a helix. 
Thus, as a result of the distinct orientation of GT within the Rho- GT complex, the ICL2 
of Rho does not interact with the hydrophobic pocket formed by the α5 helix and the β2-
β3 loop in GαT. Instead, there is only a small polar contact between N145 and the 
backbone carbonyl of S144 in ICL2, and R28 (hns1.3) from the αN-β1 juncture of GαT. 
 
Structure of nucleotide-free GT: Insights into G protein activation 
Within the cryo-EM structure for the Rho-GT complex, the most striking changes 
in the Ras-like domain of GαT, when compared to the X-ray structure for GDP-bound 
GαT 38, involve the α5 helix, which rotates upwards by about 1.25 helical turns and 
inserts into the cytoplasmic crevice of the activated Rho (Fig. 3.6a). This rotational 
translation is accomplished through a loss in the helicity of the N-terminal 5 residues of 
the α5 helix, resulting in significant rearrangements of the interactions between the α5 
helix and the remainder of the Ras-like domain. On the right side of the α5 helix (β5 and 
β6 strands) (Fig. 3.6b,c), D337 (H5.13) moves upward to contact the ICL3 of Rho and 
simultaneously interacts with Y316 (S6.2), pulling the β6 strand of GαT toward the 
receptor. The β5 strand moves closer to the N terminal portion of the α5 helix stabilizing 
this region through π-π stacking between F263 (S5.5) and F330 (H5.6).  
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Figure 3.6 Changes in GαT upon Rho binding. a, Overall structural comparison 
between GT·GDP (PDB 1GOT) and nucleotide-free GT. GαT·GDP: salmon, Gβ1γ1 in 
GT·GDP: light blue, nucleotide-free GαT: green, Gβ1γ1 in nucleotide-free GT: grey. b, 
Interactions between α5 helix and β5, β6 sheets in GαT·GDP. c, Interactions between α5 
helix and β5, β6 sheets in nucleotide-free GαT. d, Interactions between α5 helix and β2, 
β3 sheets, α1 helix in GαT·GDP. e, Interactions between α5 helix and β2, β3 sheets, α1 
helix in nucleotide-free GαT. 
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The positions of these two Phe residues clash with H318 (S6.4), pushing the C-terminal 
portion of β6 strand outward. The concerted movements in the α5 helix and β6 strand pull 
the β6-α5 loop away from interacting with the guanine base of GDP through its 
conserved TCAT motif. On the left side of the α5 helix (β2, β3 strands and α1 helix) (Fig. 
3.6d,e), its upward rotation removes the highly conserved F332 (H5.8) out of the 
hydrophobic pocket formed together with F185 (S2.6), F187 (S2.8) from β2, and F192 
(S3.3) from β3. As a result, the β2-β3 loop moves closer to α5 helix to allow F187 (S2.8) 
and F192 (S3.3) to engage F332 (H5.8) at its new position, preserving the hydrophobic 
interaction. This motion brings F185 (S2.6) from β2 into the space freed up by F332 
(H5.8), such that it contacts M49 (H1.8), pushing the α1 helix toward the N terminus of 
the α5 helix. In addition, the upward translation of the α5 helix destabilizes the position 
of the α1 helix by disrupting a hydrophobic network between V328 (H5.4) of the α5 
helix, and I45 (H1.4) and I52 (H1.11) from the α1 helix. As the α1 helix directly connects 
to the P-loop, which binds to the β phosphate of GDP, changes in the conformation of the 
α1 helix perturb the P-loop, thus loosening its contact with GDP. Moreover, given that 
both the α1 helix and β2 strand are directly linked to the helical domain, their movements 
toward the α5 helix disrupt interdomain connections and promote the dissociation of 
helical domain from the Ras domain. The structure of the GTP-bound GαT is very similar 
to that of the GDP-bound state, except for the inward movement of the Switch II region, 
which is resulted from ionic interactions formed between the N-terminal part of Switch II 
and the additional γ phosphate provided by GTP. As Switch II contributes to most of the 
contacts between GαT and Gβ1 subunits, the conformational changes in this region 
weakens the affinity of GαT for the βγ subunits. In addition, the binding of GTP causes 
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structural changes in GαT, which are reverse to the changes that happen during receptor-
promoted GDP dissociation described above. Therefore, the interactions on both the 
receptor-GαT and the Gβ1-GαT interfaces are impaired, resulting in the dissociation of the 
complex. 
In contrast to the marked changes occurring within the GαT subunit, the 
conformation of the Gβ1γ1 subunits remain very similar in the Rho-GT complex when 
compared the GDP-bound GT heterotrimer (RMSD 1.16 Å), with the exception of the 
loop connecting the last two β strands (strands C and D) in the 2nd β propeller blade of the 
Gβ1 subunit (i.e. 2nd CD loop, residues 127-KTREGNVR-134). This loop moves out of 
the β propeller by about 4 Å in the Rho-GT complex (Fig. 3.7a). The density in this 
region is not well resolved in our cryo-EM map, suggesting that the 2nd CD loop may be 
flexible in the Rho-GT complex. A previous hydrogen-deuterium exchange mass 
spectroscopy (HXMS) study on the β2AR-GS complex also showed that this is the only 
region in the GS β1 subunit that had an elevated level of flexibility upon complex 
formation39. Interestingly, when X-ray structures of the GαT helical domain from the 
GT·GDP heterotrimer were docked together with our cryo-EM Rho-GT structure into the 
low-resolution cryo-EM map for the Rho- GT complex, which has a density for the 
helical domain, the 2nd CD loop of Gβ1 is in close proximity to the αB-αC loop in the 
helical domain, enabling possible polar contacts between E111 and E112 (H.hbhc.3, 
H.hbhc.4) from the helical domain, and R129 and R134 from the Gβ1 subunit (Fig. 
3.7b,c).  
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Figure 3.7 Interaction between GαT helical domain and Gβ1. a, Overall structural 
comparison between Gβ1γ1 in GT·GDP (grey) and Gβ1γ1 in nucleotide-free GT (green). b, 
GαT helical domain orientation revealed by low-resolution cryo-EM map. c, Interaction 
between GαT helical domain and Gβ1. d, Trp fluorescence assay monitoring Rho-
catalyzed nucleotide exchange in WT GαT and helical domain mutants. 
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Mutating the two Glu residues in the helical domain significantly slowed the rate of Rho-
catalyzed nucleotide exchange (Fig. 3.7d), as read-out by changes in the intrinsic Trp 
fluorescence assay that occur as a result of the conformational changes in the Switch II 
(SW II) region of GαT40. The E111 and E112 residues lie within the solvent-exposed 
surface of GT·GDP and are not involved in any intra- or inter-domain contacts; therefore, 
the slower rate of nucleotide exchange is likely due to the disruption of their interactions 
with Gβ1 unpon complex formation. As the 2nd CD loop is directly linked through stand 
D to the 3rd DA loop (the loop connecting strand D of blade 2 to strand A of blade 3), 
which interacts with the N terminal portion of the Switch II region (SWII) in GαT (Fig. 
3.7c), the interaction with the helical domain may weaken the contact between Gβ1 and 
SWII, facilitating the release of SWII from Gβ1 upon GTP binding. The E111 and E112 
(H.hbhc.3, H.hbhc.4) residues are conserved across GT, Gi and GS, and similar 2nd CD 
loop conformations have been observed for all three G proteins in their receptor-coupled 
state. Thus, the helical domain-Gβ interaction may be a common feature utilized to 
promote complex dissociation upon GTP binding. 
 
DISCUSSION 
In conclusion, we have reported here a high-resolution cryo-EM structure of a 
Rho-GT complex formed on native retinae membrane with native Rho and GT without the 
addition of either a nanobody or an antibody fragment.  The Rho-GT complex structure 
sheds new light upon the molecular basis of the G protein activation event. It shows how 
the upward insertion of the α5 helix of the Ras-like domain of a Gα subunit into the 
cytoplasmic crevice of the activated GPCR conveys signal to the nucleotide-binding 
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pocket, through the rearrangement of key hydrophobic interactions within the Ras-like 
domain, promoting the dissociation of GDP and the opening of the helical domain. 
Moreover, analysis of a low-resolution cryo-EM map of the Rho-GT complex points to a 
potential role for the opened helical domain in facilitating the dissociation of the GPCR-
G protein complex upon GTP binding, through the interactions of the helical domain with 
the Gβ subunit, and as further corroborated by biochemical studies.  
The Rho-GT complex structure also shows that GT couples to Rho in an 
orientation that differs significantly from the GS protein, as well as the Gi protein, in other 
GPCR-G protein structures that have thus far been reported, highlighting the diverse 
modes of coupling that exist between these important signaling proteins.  Although the 
coupling specificity on the G protein part is largely determined by the residues at the C 
terminus of the α5 helix within the Ras-like domain of GαT, the specificity determinants 
on GPCRs is much more complex and are likely conferred by the cytoplasmic topology 
of the transmembrane bundle, especially the level of the TM6 outward tilt. Given the high 
degree of GPCR sequence heterogeneity, it remains difficult to predict, based on protein 
sequence, the G protein-coupling preference of a receptor41. This problem is further 
complicated by the dynamic nature of GPCR conformations42 and the fact that some of 
these receptors are able to couple to more than one G protein43. Therefore, more GPCR-G 
protein structures will be needed in order to provide better correlations between receptor 
sequence and the 3D topology of its G protein-interacting surface.  
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METHODS 
Purification of the Rho-GT complex 
The Rho-GT complex was purified in essentially the same procedure as described in 
chapter 2, except in the final gel filtration step, LMNG detergent concentration was 
reduced to 0.005% (w/v) to reduce the amount of free micelles that may interfere with 
cryo-EM particle picking. 
 
Cryo-EM data acquisition 
A sample of 3.5 µl of purified Rho-GT complex at a concentration of approximately 10 
mg·ml−1 was applied to glow-discharged holey carbon grids (Quantifoil R2/2, 300 mesh), 
and subsequently vitrified using a Vitrobot Mark IV (FEI Company). The specimen was 
visualized with a Titan Krios electron microscope (FEI) operating at 300 kV accelerating 
voltage, at a nominal magnification of 29,000× using a K2 Summit direct electron 
detector (Gatan, Inc.) in counting mode, corresponding to a pixel size of 1.0 Å on the 
specimen level. In total, 12,616 images with defocus values in the range of −1.5 to −3.0 
µm were recorded with a dose rate of about 9.0 electrons per Å2 per second. The total 
exposure time was set to 10 s with intermediate frames recorded every 0.2 s, resulting in 
an accumulated dose of about 90 electrons per Å2 and a total of 50 frames per movie 
stack.  
 
Image processing and 3D reconstructions 
Dose-fractionated image stacks were subjected to beam-induced motion correction using 
MotionCor219. A sum of all frames, filtered according to exposure dose, in each image 
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stack was used for further processing. CTF parameters for each micrograph were 
determined by CTFFIND444. Particle selection, two-dimensional classification and three-
dimensional classification were performed on a binned dataset with a pixel size of 2 Å 
using RELION45. Particle projections were selected using semi-automated procedures 
and subjected to reference-free two-dimensional classification to discard false-positive 
particles or particles categorized in poorly defined classes. An ab initio map generated 
with VIPER46 was used as initial reference model for maximum-likelihood-based 3D 
classification. Picked particles (1,656,447) were subjected to 3D classification with eight 
classes. Particles (422,637) from two best-looking classes were combined and subjected 
to another run of 3D classification with four classes. Three stable classes accounting for 
250,451 particles showed detailed features for all subunits and were combined in 
subsequent 3D refinement and reconstruction after subtracting densities for the mobile α-
helical domain and the detergent micelle from the raw micrographs. The final map has a 
global nominal resolution of 4.5 Å, based on the gold-standard Fourier shell correlation 
(FSC) using the 0.143 criterion.  
 
Model building and refinement  
The receptor structure from the Rho-GαTCT complex (PDB 3PQR) and the crystal 
structure of GDP-bound transducin heterotrimer (PDB 1GOT) were used as initial 
templates for the Rho-GT complex model. All models were docked into the EM density 
map using Chimera47, followed by iterative manual adjustment and real-space refinement 
using COOT48. The final model was subjected to global refinement and minimization in 
real space using the module phenix.real_space_refine in PHENIX49. 
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Tryptophan fluorescence assay 
Fluorescence measurements were carried out with a Varian eclipse spectrofluorimeter. 
UROS was light activated (Rho) by incubation on ice under ambient light for 5 min. Rho-
catalyzed nucleotide exchange on the αT subunit in detergents was monitored by 
premixing 5 nM Rho and 300 nM β1γ1 in HMN buffer (20 mM HEPES, pH 7.5, 2 mM 
MgCl2, 100 mM NaCl, 1 mM DTT) with 50 µM GTPγS and 0.01% (w/v) LMNG 
detergent, monitoring tryptophan fluorescence (excitation: 300 nm; emission: 345 nm) in 
real-time upon the addition of 300 nM αT. 
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Chapter 4 
 
Conclusion 
 
G protein-coupled receptors (GPCRs) comprise the largest known family of 
integral membrane proteins and are encoded by over 1% of the genome in vertebrates1. 
They are responsible for sensing a vast range of extracellular signals and control cellular 
responses through activation of heterotrimeric G proteins. As a result of the diverse roles 
played by GPCRs in human physiology, these membrane receptors represent the most 
exploited type of drug targets with over 30% of small molecule drugs used today 
targeting this membrane protein family2. Therefore, structural information of GPCRs, 
especially GPCRs in their G protein-interacting active state, is of great importance. 
However, due to the intrinsic structural plasticity of GPCRs and their biochemical 
instability, structural determinations of GPCRs have proven to be extremely challenging. 
In my thesis research, I have utilized the vertebrate visual phototransduction 
cascade as a model system for studying GPCR-G protein interactions. In this system, the 
photoreceptor molecule rhodopsin is a prototypical GPCR and is the founding member of 
the largest GPCR subfamily, the rhodopsin-like family. Rhodopsin has a covalently 
bound ligand, 11-cis retinal, which functions as an inverse agonist that stabilizes 
rhodopsin in its inactive state in the dark. The absorption of photons induces the 
isomerization of 11-cis retinal to all-trans retinal, which becomes an agonist for the 
receptor, causing structural changes at its intracellular surface. Activated rhodopsin 
catalyzes the nucleotide exchange within its cognate heterotrimeric G protein-signaling 
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partner transducin, which is a member of the inhibitory Gi protein family. The GTP-
bound transducin then interacts with the downstream effector enzyme, cGMP 
phosphodiesterse (PDE6), and results in the reduction of cytosolic levels of the second 
messenger molecule, cGMP. The phototransduction system is highly advantageous for 
structural studies, as all of its component proteins can be purified from native tissue, 
bovine retinae, in milligram amounts. 
In chapter 2, I utilized the purified retinal rod outer segment membranes, which is 
naturally enriched in rhodopsin (about 50% of the membrane area is occupied by 
rhodopsin3), and was able to form a nucleotide-free rhodopsin-transducin complex on the 
native membrane upon light exposure. The resulting membranes were then pelleted down 
by centrifugation to remove dissociated GDP and free transducin molecules. The 
rhodopsin-transducin complex was extracted through solubilization with the detergent 
lauryl maltose neopentyl glycol (LMNG)4, which has been identified as being able to 
maintain complex stability over a wide concentration range, as monitored by using the 
changes in the intrinsic tryptophan fluorescence that occur within αT during rhodopsin-
catalyzed nucleotide exchange5. The solubilized complex was then purified with a 
combination of immobilized metal affinity chromatography (IMAC) and gel filtration 
steps. The resulting complex is composed of one rhodopsin molecule and one transducin 
molecule based on both UV-Vis spectroscopy and radioactive nucleotide-binding assays. 
The purified complex was then further characterized with negative-stain electron 
microscopy (EM) and small-angle X-ray scattering (SAXS), which revealed that the 
complex is monodisperse and has a similar overall architecture to the previously 
characterized β2 adrenergic receptor-GS protein complex. Similar to what has been 
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observed for the β2 adrenergic receptor-GS protein complex6, the helical domain of the 
transducin α subunit adopts an open conformation in the rhodopsin-transducin complex 
and has a certain degree of flexibility. 
In chapter 3, I and my collaborators utilized cryo electron microscopy (cryo-EM) 
to obtain a 4.5Å structure of the detergent-solubilized rhodopsin-transducin complex 
without the addition of any stabilizing nanobody or antibody fragments. The local 
resolution is highest at the receptor core and the receptor-G protein interface, allowing 
me to model most of the amino acid side chains in these regions. Our structural model 
revealed that transducin engages rhodopsin mostly through the C terminal helix of its α 
subunit and interacts mainly with transmembrane helix (TM) 5, TM6 and the loop that 
links them, intracellular loop 3 (ICL3). This mode of interaction is significantly different 
than what has been observed in both recent receptor-GS protein complex structures7–10 
and other GPCR-Gi complex structures11–13, in which the G protein α subunit binds the 
receptor at both ICL2 and the TM5-ICL3-TM6 region. As a result of the strikingly 
different interaction preferences, the overall orientation of the G protein transducin in the 
complex is distinct from those observed in other GPCR-G protein complexes. In addition, 
our cryo-EM map, before refinement, revealed a density for the helical domain of the αT 
subunit that is located next to the density of the β subunit, suggesting a possible 
interaction between them. Mutations of polar residues on the helical domain that have 
been predicted to contact the β subunit based on the cryo-EM map significantly reduced 
the rate of rhodopsin-catalyzed nucleotide exchange as monitored by the tryptophan 
fluorescence assay. These results point to an active role played by the helical domain and 
the β subunit in promoting receptor-mediated G protein activation. 
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Included in appendix chapters 1 and 2 are detailed protocols for purifying the 
rhodopsin-transducin complex and reconstitution of the detergent-solubilized complex 
into lipid nanodisc particles. 
The G protein transducin shares the same β1 subunit with the GS protein. As the 
nanobody Nb35, which was raised against the β2 adrenergic receptor-GS protein complex, 
binds at the interface between α and β subunits7, we hypothesized that it should be 
possible to generate a similar nanobody for the rhodopsin-transducin complex by only 
mutating residues on the interface between the α subunit and Nb35. Based on a homology 
model generated with the structure of the nucleotide-free GS α subunit14, we introduced 
12 mutations within the αT subunit and 3 additional mutations on Nb35 (Fig. 4.1a). The 
mutations introduced on the α subunit did not impair its ability to undergo rhodopsin-
catalyzed nucleotide exchange and the nanobody mutant was able to bind the rhodopsin-
transducin complex formed with the mutated αT subunit in high affinity, as demonstrated 
by the 1:1 ratio co-elution of the complex and nanobody in size exclusion 
chromatography (Fig. 4.1b). We have applied the rhodopsin-transducin-nanobody 
complex to cryo-EM structural determination and were able to obtain a 3.4Å-resolution 
map for the complex. I am currently in the process of refining the cryo-EM map and 
building a structural model based on the data. The higher-resolution nanobody complex 
will make it possible to visualize the rhodopsin-transducin complex in much finer detail 
and through comparison with the previous structure of the rhodopsin-transducin complex 
without nanobody, shed light on the possible perturbations caused by nanobody-binding 
on receptor-G protein complexes.  
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Figure 4.1 Engineering of nanobody that binds to the rhodopsin-transducin 
complex. a, A homology model of transducin α subunit overlaid with the nucleotid-free 
GS α subunit (PDB 3SN6) illustrating the interface between Nb35 and the α subunit. The 
transducin α subunit is in red, GS α subunit is in green and Nb35 is in yellow. b, Gel 
filtration profiles and SDS-PAGE gel showing the nanobody binding to rhodopsin-
transducin complex. 
 
 
 
 
 
 
 
 
 
 
	 114	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 115	
We are also planning on utilizing interesting transducin α subunit mutants previously 
developed in our lab, such as the S43N mutant15, which remains associated with 
rhodopsin even in the presence of GTP. Structures of complexes formed with transducin 
mutants would allow us to capture the GPCR-G protein signaling complex in various 
states along the G protein activation process and would provide invaluable mechanistic 
details for understanding this important signaling pathway. 
In addition to providing a source for milligram quantities of rhodopsin and 
transducin molecules, the vertebrate visual phototransduction system also allows for 
extraction of the native effector enzyme PDE6. PDE6 is a prototypical member of the 
cyclic nucleotide PDE enzyme family, which contains 11 related gene families coding 
about 100 protein isoforms16. PDEs regulate the level of cyclic nucleotide second 
messenger molecules, cAMP and cGMP, in cells by catalyzing their hydrolysis. As PDEs 
play a critical role in almost every regulatory system in the body, they are highly valued 
pharmaceutical targets. PDE6 is composed of four subunits, two non-identical catalytic 
subunits α and β (each about 100 kD) and two identical inhibitory γ subunits (about 10 
kD). Each catalytical subunit (α and β) contains two tandem GAF domains and a C-
terminal catalytic domain, which is isoprenylated for membrane association. A major 
question in the field is how GTP-bound Gα activates PDE6. The consensus nowadays is 
that Gα·GTP binds PDEγ and displaces, but does not dissociate, PDEγ from the catalytic 
subunits. As PDE6 has two binding sites (two PDEγ) for Gα·GTP, it is not clear whether 
it needs two or one Gα·GTP to become fully active and whether the two catalytic 
subunits α and β behave equally in catalyzing cGMP hydrolysis. Previous strudies in our 
lab utilizing a transducin C-terminal peptide specific antibody AS/7 have shown that 
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complexation between this antibody and the GTP-bound transducin α subunit in a 1:2 
ratio resulted in a 2-5 fold potentiation of PDE6 activity, suggesting the possible 
existence of a 2:1 transducin:PDE6 complex17. Additionally, we have also previously 
identified a PDE γ subunit mutant that only binds to one of the two binding sites on the 
catalytic PDE α and β subunits and is incapable of inhibiting the activity of the enzyme18. 
This finding points to the conclusion that the binding sites on the PDE α and β subunits 
are different. We are currently in the process of utilizing cryo-EM to determine a high-
resolution structure of the PDE6 holoenzyme in its inactive form and are also working on 
purifying a stable complex between GTP-bound transducin α subunit and activated PDE6 
enzyme. 
In summary, we have utilized the vertebrate visual phototransduction system to 
characterize GPCR-G protein interactions, and have been able to obtain a 4.5 Å structure 
of a nucleotide-free GPCR-G protein complex, the rhodopsin-transducin complex, which 
has furthered our understanding of the receptor-mediated G protein activation process. 
This model system also provides the potential for future structural studies of G protein-
effector interactions and has proven to be an invaluable system for studying the GPCR-G 
protein signaling cascade. 
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Appendix Chapter 1 
 
Protocol for Purification of the Rhodopsin-Transducin Complex 
 
INTRODUCTION 
G protein-coupled receptors (GPCRs) comprise the largest family of 
transmembrane proteins in humans with about 800 members1 and are targets for over 
30% of all drugs on the market2. They share a signature structural motif of seven 
transmembrane helixes and transmit signals from a vast array of extracellular stimuli, 
including hormones, neurotransmitters, odorant and photons, across the plasma 
membrane3 and thus modulate a wide range of cellular responses. This process is 
achieved mostly through the activation of their canonical signaling partners, 
heterotrimeric G proteins, which are composed of three subunits, the nucleotide-binding 
α subunit and two constitutively associated subunits β and γ. And they can be classified 
into four different types based on the amino acid sequence similarity of the α subunits: GS, 
Gi, Gq and G124.  
Despite the striking diversity of the GPCR family, in humans there are only 16 
genes encoding 21 different α subunits5. And thus each G protein must be able to interact 
with a large number of different GPCRs. Furthermore there have been evidence showing 
that some GPCRs, for example the β2 adrenergic receptor6, can couple to more than one 
G proteins. Therefore proper regulation of the specificity between GPCRs and G proteins 
is vital for signal transduction inside cells. However, due to the intrinsic flexibility and 
instability of GPCRs and the GPCR-G protein complexes, it has been very challenging to 
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extract and purify these proteins and elucidate the structural mechanism underlying this 
specificity.  
In recent years, with the development of a wide range of techniques, including 
novel protein engineering7, in meso crystallization8, micro-focus beamlines9 at 
synchrotron facilities, and cryo-electron microscopy10, the number of GPCR structures 
have been growing almost exponentially, among which three are high-resolution 
structures of GPCR-G protein complexes, namely the β2 adrenergic receptor-GS protein 
complex (solved by X-ray crystallography)11 and the calcitonin receptor-GS protein 
complex12 and the glucagon-like peptide 1 receptor- GS protein complex13 (both solved 
with cryo-electron microscopy). As all these complex structures are of the same G protein 
GS, structural information of complexes formed with different classes of G proteins 
would be crucial for understanding the specificity between GPCRs and G proteins. And 
to this end, the visual photo-transduction cascade would be an ideal system, as its G 
protein transducin belongs to the Gi family. 
The visual photo-transduction system is a prototypical GPCR-signaling system. 
Rhodopsin, the GPCR, has a covalently bound inverse agonist 11-cis retinal which photo-
isomerizes into all-trans retinal and becomes an agonist for rhodopsin upon light-
activation. Light-activated rhodopsin then binds and catalyzes the exchange of GDP for 
GTP in the heterotrimeric G protein transducin (GT, subunits designated as αT, β1 and γ1). 
The GTP-bound αT can then turn on cGMP phosphodiesterase (PDE) which hydrolyzes 
cGMP to GMP, eventually leading to visual neuron signals14. This system offers certain 
advantages for obtaining structural insights into GPCR-signaling, as each of the principle 
components can be purified from native tissue in large quantities. As a result, rhodopsin 
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represents the first and only GPCR for which X-ray crystal structures15-19 have been 
solved in the native form. 
Here we present a method for extracting and purifying the complex between light-
activated rhodopsin and nucleotide-free transducin directly from the native retinal 
membranes20 (as shown in Fig. 5.1) using proteins components purified from bovine 
retinae and an αT/αi1 chimera (αΤ) which can be expressed in E coli and undergo 
rhodopsin catalyzed nucleotide exchange and activate PDE in a similar manner as native 
αT21. Forming the complex on membrane allows for easy seperation of the proteins from 
the GDP dessociated from GT upon activation by centrifugation, which is destabilizing 
for the complex. Moreover, as both rhodopsin and GT are lipid-modified (rhodopsin is 
palmitolated at its C-terminus22, αT has N-terminal myristoylation23 and γ1 is farnesylated 
at the C-terminus24), formation of the complex on membrane prior to detergent-extraction 
would allow for proper engagement among these lipid modifications. The resulting 
complex can then be solibilized with a mild detergent lauryl maltose neopentyl glycol 
(LMNG), extracted by utilizing a His6-tag on αΤ and further purified with size-exclusion 
chromatography (SEC). The purified complex has a 1:1 ratio of rhodopsin to transducin, 
which can be verified with UV-Vis spectroscopy, as the ligand all-trans retinal has a 
distinct absorbtion as 380 nm. The complex is very stable and can be stored at 4 °C in the 
dark for over a week without suffering from much dissociation. This method can also 
potentially be applied to other recombinantly expressed receptors from insect cells or 
mamalian cells by forming complexes directly on purified cell membranes. 
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Figure 5.1 Rhodopsin-transducin complex purification scheme 
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MATERIALS 
Formation and extraction of the rhodopsin-transducin complex 
1. Bovine retinae can be obtained from W L Lawson Company (Omaha, NE). 
2. HMN buffer: 20 mM HEPES pH 7.5, 2 mM MgCl2, 100 mM NaCl, 100 µM TCEP. 
3. The detergent lauryl maltose neopentyl glycol (LMNG) can be obtained from Anatrace 
and all other chemicals can be purchased from either Sigma or VWR. 
4. Aluminum foil. 
5. A tabletop microcentrifuge and an end-to-end rocker kept in a cold room at 4 °C. 
6. 1.7 mL microcentrifuge tubes and 15 mL conical tubes. 
7. A desk lamp with standard UV filter. 
8. Floor lamps covered with 3M 616 lithographer’s tape. 
Chromatographic purification of the rhodopsin-transducin complex 
1. A 1 mL HisTrap HP column (GE Life Sciences) 
2. An FPLC equipped with a UV absorbance monitor set at 280 nm and a fraction 
collector and kept in a cold box at 4 °C. A desk lamp covered with 3M 616 lithographer’s 
tape. 
3. HisTrap buffer A: 20 mM HEPES pH 7.5, 2 mM MgCl2, 100 mM NaCl, 100 µM 
TCEP, 0.02% LMNG. 
4. HisTrap buffer B: HisTrap buffer A + 500 mM imidazole pH 7.5. 
5. A Superdex 200 10/300 GL column (GE Life Sciences) 
6. SEC buffer: 20 mM HEPES pH 7.5, 2 mM MgCl2, 100 mM NaCl, 100 µM TCEP, 
0.003% LMNG. 
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7. Amicon Ultra-0.5 mL centrifugal filters with 100 kD molecular weight cutoff (EMD 
Millipore). 
Characterization of the purified complex with UV-Vis spectroscopy and analytical 
SEC 
1. A UV-Vis spectrophotometer. 
2. A Superdex 200 10/300 GL column (GE Life Sciences) 
3. An FPLC equipped with a UV absorbance monitor set at 280 nm and a fraction 
collector and kept in a cold box at 4 °C. A desk lamp covered with 3M 616 lithographer’s 
tape. 
4. SEC buffer: 20 mM HEPES pH 7.5, 2 mM MgCl2, 100 mM NaCl, 100 µM TCEP, 
0.003% LMNG. 
 
METHODS 
Formation and extraction of the rhodopsin-transducin complex 
1. Both dark-state rhodopsin (in the form of urea-washed rod outer segment membrane) 
and transducin β1γ1 subunits can be purified from bovine retinae as described 
previously25-26 and are stored in HMN buffer with 10% glycerol at -80 °C. Typical 
concentrations of rhodopsin and β1γ1 are 280 µM and 40 µM respectively. (see Note 1) 
2. The N-terminally His6-tagged αT/αi1 chimera (αΤ), in which residues from 215 to 295 
in αT, except for residues 244 and 247, are replaced with corresponding residues from αi1, 
can be expressed and purified from E coli BL21(DE3) as described previously21 and 
stored in HMN buffer with 10% glycerol at 44 µM concentration at -80 °C. (see Note 2) 
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3. Thaw one 500 µL aliquot each of rhodopsin, αΤ and β1γ1 on ice and mix them in a 1.7 
mL microcentrifuge tube, resulting in 7:1.1:1 molar ratio of rhodopsin:αΤ:β1γ1. Incubate 
mixture on ice in the dark for 5 min. (see Note 3 and 4) 
4. In a cold room, lay the tube containing the mixture on to a end-to-end rocker and place 
a desktop lamp about 10 cm above the tube. Turn on both the rocker and the lamp and 
expose to mixture to light for about 20 min. (see Note 5) 
5. All following steps should be carried out in the dark with red lights. Spin the tube at 
16,000 g in a tabletop microcentrifuge for 30 min in the cold room. 
6. Carefully asperate out and discard the supernatant. The rhodopsin-transducin complex 
and excess rhodopsin will be in the membrane pellet at the bottom of the tube. 
7. Resuspend the pellet with 2 mL cold HMN buffer with 1% LMNG and transfer the 
suspension into a 15 mL conical tube. Wrap the tube in foil and gently rock it in the cold 
room for 30 min. (see Note 6) 
8. Add 8 mL cold HMN buffer to the tube and wrap the tube in foil again and gently rock 
it in the cold room for an additional 60 min. 
Chromatographic purification of the rhodopsin-transducin complex 
1. Equilibrate a 1 mL HisTrap HP column with 10 mL HisTrap buffer A at 1 mL/min on 
an FPLC equipped with a UV absorbance monitor set at 280 nm. (see Note 7) 
2. Add 0.2 mL HisTrap buffer B to the solubilized complex and load the mixture onto the 
column at 1 mL/min. (see Note 8) 
3. Wash the column with 20 mL 4% B at 1 mL/min. (see Note 9) 
4. Elude with a 10 mL 4-40% B gradient and an additional 10 mL 40% B step gradient at 
1 ml/min. Collect 1 mL fractions. (see Note 10) 
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5. Concentrate the fractions containing the complex with two 0.5 mL 100 kD molecular 
weight cutoff Amicon concentrators at 14,000 g for 3 min each time in a tabletop 
microcentrifuge kept in a dark cold room with red lights. And wash three times with 
HisTrap buffer A on the concentrators to remove imidazole. Final volume of the complex 
is about 200 µL. At this stage the complex can be either stored wrapped in foil on ice 
overnight or used directly for the next step.  (see Note 11) 
6. Equilibrate a Superdex 200 10/300 GL column with 60 mL SEC buffer at 0.4 mL/min. 
7. Inject the complex from step 5 onto the column run at 0.4 mL/min with SEC buffer. 
Collect 0.4 mL fractions. (a typical SEC profile is shown in Fig. 5.2) 
8. Pool fractions containing the complex from step 7 and concentrate with a 0.5 mL 100 
kD molecular weight cutoff Amicon concentrator to about 100 µL. This is the final 
purified complex and the concentration should be about 10 mg/mL. (see Note 12) 
Characterization of the purified complex with UV-Vis spectroscopy and analytical 
SEC 
1. The concentration of the complex can be measured with a UV-Vis spectrophotometer 
at 280 nm (A280nm) using the extinction coefficient ε280nm=155070 M-1cm-1, and molecular 
weight Mw=126040 Da. (see Note 13) 
2. The purity of the complex can be assessed with UV-Vis spectroscopy by measuring the 
absorbance at 280 nm (A280nm, the absorbance of the protein moieties) and 380 nm 
(A380nm, the absorbance of all-trans retinal) (a typical spectrum is shown in Fig. 5.3A). 
The A280nm/ A380nm ratio should be 3.69, indicating a 1:1 rhodopsin:transducin complex. If 
the complex is contaminated with excess GT of excess rhodopsin, the ratio will be either 
higher or lower than 3.69. (see Note 14) 
	 128	
 
 
 
 
 
 
 
 
 
 
Figure 5.2 SEC profile of rhodopsin-transducin complex purification and SDS-
PAGE gel of concentrated peak fractions 
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Figure 3.  UV-Vis spectrum and analytical SEC profiles of the purified rhodopsin-
transducin complex A, UV-Vis spectrum of purified complex. B, Analytical SEC 
profiles of Day 1 (blue) and Day 7 (orange) complexes. 
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3. The integrity of the complex can be routinely assessed with analytical SEC by 
injecting 5 µL of 10 mg/mL complex diluted with SEC buffer to 100 µL onto a Superdex 
200 10/300 GL column pre-equilibrated with SEC buffer run at 0.4 mL/min. The 
complex will elute as a sharp symmetrical peak if it is intact (typical analytical SEC 
profiles shown in Fig. 5.3B). The purified complex is generally stable for over a week 
when kept at 4 °C wrapped in foil. 
 
NOTES 
1. Typically about 300 mg of rhodopsin and 15 mg of β1γ1 can be purified from 300 
bovine retinae. All proteins can be aliquoted into 500 µL aliquots in 1.7 mL 
microcentrifuge tubes, resulting in 140 nM rhodopsin, 20 nM β1γ1 and 22 nM αΤ in each 
tube. Rhodopsin aliquots should be wrapped in foil individually to avoid exposure to 
light. 
2. The 10% molar excess of αΤ ensures that all β1γ1 is utilized as β1γ1 is harder to purify 
and more valuble than αΤ. 
3. The large molar excess of rhodopsin is necessary because rhodopsin is very densely 
packed on retinal membrane and as a result a large portion of it is not easily accessible to 
transducin. This is not necessary if using membranes from insect cells or mammalian 
cells. 
4. Extra care must be taken to ensure that rhodopsin is not exposed to light prior to the 
following light activation step. 
5. To provide a controlled light exposure, all other lights in the cold room should be 
turned off. All following steps should be conducted in the dark with red lights. 
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6. Prolonged incubation in 1% LMNG will cause the complex dissociation. 
7. The FPLC should be kept in a cold box set at 4 °C with the glass doors covered with 
foil to prevent light exposure inside and a red light can be kept inside the cold box to 
facilitate visuallization. 
8. The addition of 0.2 mL buffer B results in a imidazole concentration of 10 mM which 
prevents the binding of excess rhodopsin to the column. 
9. This step further removes contamination from excess rhodopsin and also lowers the 
detergent concentration from 0.2% to 0.02%. 
10. The complex will start to come off the column at around 10% B and peak at 40% B. 
11. Prolonged incubation with imidazole can destabilize the complex. Therefore, it is 
necessary to remove imidazole if complex were to be stored overnight. It is recommeded 
to concentrate the fractions starting from those with high imidazole concentrations, and 
as a result the final imidazole concentration before washing will be much lower. During 
concentrating and washing, it is recommended to invert the concentrators several times to 
alleviate protein aggregation during centrifugation. 
12. The complex peak will be contained in four 0.4 mL fractions. During concentrating 
and washing, it is recommended to invert the concentrators several times to alleviate 
protein aggregation during centrifugation. 
13. Concentration (in mg/mL) = A280nm×Mw/ε280nm.  
14. The extinction coefficients used are as follows: rhodopsin (ε280nm = 61,800 M-1cm-1, 
ε380nm = 42,000 M-1cm-1), αT (ε280nm = 35,870 M-1cm-1), and β1γ1 (ε280nm = 57,400 M-1cm-
1). 
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Appendix Chapter 2 
 
Reconstitution of Rhodopsin-Transducin Complex into Lipid Nanodiscs 
 
INTRODUCTION 
Transmembrane proteins, such as G protein-coupled receptors (GPCRs), are not 
soluble in aqueous solutions due to the presence of large hydrophobic surfaces, which are 
necessary for their insertion into lipid bilayers. Therefore, in order to maintain proper 
folding, detergents are required during the extraction of these proteins from the 
membrane. And in the case of GPCRs, as they adopt a high level of structural flexibility1, 
most conventional detergents, for example octyl glucoside (OG) and dodecyl maltoside 
(DDM) are not sufficient for maintaining their stability and signaling activities. Recently, 
a series of novel detergents, such as maltose neopentyl glycol (MNG) 2 and glyco-
diosgenin (GDN) 3, have been developed featuring a more rigid architecture, which is 
intended to place subtle restraints on protein conformational flexibility. And they have 
proven to be very successful at sustaining the structural integrity and activity of GPCRs 
and have helped usher in the recent rapid growth in the number of high-resolution GPCR 
and GPCR-G protein complex structures. However, despite the high stability of GPCRs 
in MNG and GDN, the hydrophobic environment provided by the detergent micelles is 
still very different from the native membrane environment, as these detergents tend to 
have very large micelles that are much thicker than lipid membranes and may distort the 
conformation of hydrophilic residues close to the hydrophobic belt. In addition, GPCRs 
have been known to interact with lipids in the membrane. For example, the 
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photochemical properties4 of the GPCR rhodopsin in the visual phototransduction 
pathway and its coupling efficiency to the heterotrimeric G protein transducin5 are 
sensitive to its lipid environment composition and tightly bound phospholipids molecules 
have been seen in a high-resolution rhodopsin crystal structure6. Moreover, GPCRs are 
often palmitoylated on one or more cysteines at the intracellular side7, and a lipid bilayer 
environment would allow for proper orientation of these lipid modifications. Therefore, it 
is clear that a reconstituted lipid bilayer environment would be the best conduit for 
studying the biophysical properties of GPCRs and nanodiscs provide a perfect solution to 
address this challenge.  
Nanodiscs are comprised of a circular lipid bilayer center, into which a 
transmembrane protein can be incorporated, and two molecules of membrane scaffold 
protein (MSP), which is a modified form of human high-density lipoprotein apoA-18. 
MSP contains a series of amphipathic α helixes that can wrap around the lipids and thus 
stabilize the bilayer disc in aqueous solutions. The size of the nanodiscs is very 
monodisperse and can be easily adjusted by varying the number of amphipathic helixes in 
MSP9-10. In the case of rhodopsin, the GPCR in the visual phototransduction pathway, 
nanodiscs have been used to study the stoichiometry of its interaction with the G protein 
transducin11-12, rhodopsin kinase and arrestin13. And more recently double electron-
electron resonance (DEER) has been used to characterize rhodopsin incorporated into 
nanodiscs and revealed that the activated receptor is in equilibrium among multiple 
conformations which is very different from the single conformation observed in DDM 
micelles14. Moreover, with the recent development in cryo-electron microscopy 
technology15, nanodiscs have proven to be a great environment for obtaining high-
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resolution structures of transmembrane proteins, as it helps maintain them in a native-like 
environment and can allow for interactions between annular phospholipids and proteins16.  
Here we present a method for reconstituting the purified detergent-solubilized 
rhodopsin-transducin complex17, the GPCR-G protein complex in visual 
phototransduction, (as described in a previous chapter) into nanodiscs. A truncated 
version of MSP (MSP1D1ΔH5)18 was chosen as the size of the resulting nanodiscs is 
only big enough to accommodate one receptor complex, thus ensuring a homogeneous 
preparation. The process starts with mixing purified complex with MSP and lipids 
solubilized in detergents in a specific ratio and then the detergent can be slowing 
removed by incubation with Bio-Beads. During detergent removal, the nanodiscs self-
assemble and incorporate the receptor complex. The resulting complex-embedded 
nanodiscs can then be further purified with size exclusion chromatography (SEC). As the 
receptor rhodopsin has a covalently bound agonist all-trans retinal, which has a distinct 
UV absorption at 380 nm, the 1:1 ratio between nanodisc and complex can be verified by 
UV-Vis spectroscopy. The purified complex-embedded nanodiscs can be used in further 
biophysical characterizations, such as small-angle X-ray scattering (SAXS) and negative-
stain electron microscopy, and potentially be applied to cryo-electron microscopy for 
obtaining high-resolution structures of the rhodopsin-transducin complex. In addition, as 
the composition of the lipids used in nanodisc formation can be varied, the resulting 
nanodiscs can also be used for studying the effects of different lipids on this GPCR-G 
protein complex. 
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MATERIALS 
Incorporation of rhodopsin-transducin complex into nanodiscs 
1. The lipid 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) can be obtained 
from Avanti Polar Lipids and all other chemicals can be purchased from either Sigma or 
VWR. 
2. HMN buffer: 20 mM HEPES pH 7.5, 2 mM MgCl2, 100 mM NaCl, 100 µM TCEP. 
3. 10% (w/v) sodium cholate in HMN buffer. 
4. Methanol 
5. Purified rhodopsin-transducin complex in HMN buffer plus 0.003% lauryl maltose 
neopentyl glycol as described in previous chapter.  
6. Bio-Beads SM-2 resin can be obtained from Bio-Rad. 
7. A sonic dismemrator. 
8. A scale accurate to 0.1 mg. 
9. A tabletop microcentrifuge and an end-to-end rocker kept in a cold room at 4 °C. 
10. 0.7 mL and 1.7 mL microcentrifuge tubes. 
11. 1 mL disposable syringes with Luer-Lok tips. 
12. 0.22 µm PVDF syringe filters 
13. Aluminum foil. 
14. Floor lamps covered with 3M 616 lithographer’s tape. 
SEC purification of rhodopsin-transducin complex embedded nanodiscs 
1. An FPLC equipped with a UV absorbance monitor set at 280 nm and a fraction 
collector and kept in a cold box at 4 °C. A desk lamp covered with 3M 616 lithographer’s 
tape. 
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2. A Superdex 200 10/300 GL column (GE Life Sciences) 
3. HMN buffer: 20 mM HEPES pH 7.5, 2 mM MgCl2, 100 mM NaCl, 100 µM TCEP. 
4. Amicon Ultra-0.5 mL centrifugal filters with 100 kD molecular weight cutoff (EMD 
Millipore). 
5. A tabletop microcentrifuge kept in a cold room at 4 °C. 
6. Aluminum foil. 
7. Floor lamps covered with 3M 616 lithographer’s tape. 
Characterization of the complex-embedded nanodiscs with UV-Vis spectroscopy 
1. A UV-Vis spectrophotometer. 
 
METHODS 
Incorporation of rhodopsin-transducin complex into nanodiscs 
1. The membrane scaffolding protein MSP1D1ΔH5 can be expressed and purified from E 
coli BL21(DE3) as described previously9 using a pET28a vector harboring an N-terminal 
His6-tag DNA sequence followed by the MSP1D1 gene with DNA sequence 
corresponding to residues 121-142 deleted and stored in HMN buffer with 10% glycerol 
at 300 µM concentration at -80 °C. (see Note 1) 
2. Weigh out 5 mg POPC in a 0.7 mL microcentrifuge tube. Add 75 µL HMN buffer to 
the lipid and vortex for 1 min to achieve a uniform suspension. Sonicate the tube at 
maximum intensity in water bath for 1 min. Add 56.6 µL 10% (w/v) sodium cholate to 
the suspension and vortex the mixture for 1 min. Sonicate the tube at maximum intensity 
in water bath for 1 min. This result in 50 mM POPC solubilized in HMN buffer 
containing100 mM sodium cholate. (see Note 2) 
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3. Weigh out 200 mg Bio-Beads in a 1.7 mL microcentrifuge tube. Incubate with 1.5 mL 
methanol for 1 min. Spin the tube in a tabletop microcentrifuge for 0.5 min at maximum 
speed. Gently aspirate out and discard the supernatant. Repeat this process with 1.5 mL 
HMN buffer instead for three times and store the equilibrated Bio-Beads on ice. 
4. The ratio between MSP, lipids and the rhodopsin-transducin complex is critical for 
obtaining homogeneous complex-embedded nanodiscs. The optimal molar ratio is 1:3:50 
complex:MSP1D1ΔH5:POPC. (see Note 3) 
5. Mix 50 µL 300 µM MSP1D1ΔH5 with 5 µL 50 mM POPC from step 2, resulting in 
3:50 ratio of MSP1D1ΔH5:POPC. Incubate on ice for 20 min. 
6. All following steps should be carried out in the dark with red lights. Add 5.3 µL 10% 
sodium cholate (232.6 mM) and 63.1 µL 10 mg/mL (79.3 µM) purified rhodopsin-
transducin complex to the mixture and incubate on ice for another 20 min. (see Note 4) 
7. Weigh out 123 mg wet Bio-Beads in a 0.7 mL microcentrifuge tube. Add the mixture 
from step 6 to the tube, wrap the tube with foil and incubate it on an end-to-end rocker in 
a cold room set at 4 °C overnight. (see Note 5) 
8. Spin the tube from step 7 in a tabletop microcentrifuge kept in a dark cold room with 
red lights for 0.5 min at maximum speed. Gently aspirate out the supernatant and filter it 
with a 0.22 µm PVDF syringe filter. 
SEC purification of rhodopsin-transducin complex embedded nanodiscs 
1. Equilibrate a Superdex 200 10/300 GL column with 60 mL HMN buffer at 0.4 mL/min 
on an FPLC equipped with a UV absorbance monitor set at 280 nm and a fraction 
collector. (see Note 6) 
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2. Inject the complex-embedded nanodiscs from the previous section onto the column run 
at 0.4 mL/min with HMN buffer. Collect 0.4 mL fractions (a typical SEC profile is 
shown in Fig. 6.1). 
3. Pool fractions containing the complex-embedded nanodiscs from step 2 and 
concentrate the fractions with one 0.5 mL 100 kD molecular weight cutoff Amicon 
concentrator to about 100 µL at 14,000 g for 3 min each time in a tabletop 
microcentrifuge kept in a dark cold room with red lights. This is the final purified 
complex-embedded nanodiscs and the concentration is typically about 3 mg/mL.  The 
nanodiscs can be stored wrapped in foil at 4 °C for over a week. (see Note 7) 
Characterization of the complex-embedded nanodiscs with UV-Vis spectroscopy 
1. The concentration of the complex-embedded nanodiscs can be measured with a UV-
Vis spectrophotometer at 280 nm (A280nm) using the extinction coefficient ε280nm=197,930 
M-1cm-1, and molecular weight Mw=170,240 Da. (see Note 8) 
2. The number of rhodopsin-transducin complexes in each nanodisc can be assessed with 
UV-Vis spectroscopy by measuring the absorbance at 280 nm (A280nm, the absorbance of 
the protein moieties) and 380 nm (A380nm, the absorbance of all-trans retinal) (a typical 
spectrum is shown in Fig. 6.2). The A280nm/ A380nm ratio should be 4.70, indicating a 1:1 
molar ratio of complex:nanodisc. (see Note 9) 
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Figure 6.1 SEC profile of complex-embedded nanodiscs and SDS-PAGE gel of 
concentrated peak fractions. 
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Figure 6.2 UV-Vis spectrum of the purified complex-embedded nanodiscs 
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NOTES 
1. The protein sequence of MSP1D1ΔH5 is as follows: 
MGHHHHHHDYDIPTTENLYFQGSTFSKLREQLGPVTQEFWDNLEKETEGLRQEM
SKDLEEVKAKVQPYLDDFQKKWQEEMELYRQKVEPLGEEMRDRARAHVDALR
THLAPYSDELRQRLAARLEALKENGGARLAEYHAKATEHLSTLSEKAKPALEDL
RQG LLPVLESFKVSFLSALEEYTKKLNTQ 
2. The lipids (stored at -20 °C) are hygroscopic and should be allowed to come to room 
temperature before opening the vial. The detergent-solubilized lipids can be stored at -80 
°C for up to 6 months. 
3. The excess MSP and lipids ensures only one complex is incorporated into each 
nanodisc. If MSP1D1 is used, the ratio should be 1:3:145 complex:MSP1D1:POPC. 
4. The addition of 10% sodium cholate maintains the cholate concentration at 14 mM, 
above its cmc of 9.5 mM. As the rhodopsin-transducin complex is light sensitive, all 
steps onward should be conducted in the dark with red lights. 
5. The ratio of Bio-Beads to nanodisc mixture is 1 mg wet Bio-Beads to 1 µL solution. 
6. The FPLC should be kept in a cold box set at 4 °C with the glass doors covered with 
foil to prevent light exposure inside and a red light can be kept inside the cold box to 
facilitate visuallization. 
7. The complex-embedded nanodiscs peak will be contained in four 0.4 mL fractions. 
During concentrating, it is recommended to invert the concentrators several times to 
alleviate protein aggregation during centrifugation. 
8. Concentration (in µM) = A280nm×106/ε280nm. Concentration (in mg/mL) = 
A280nm×Mw/ε280nm. 
	 150	
9. The extinction coefficients used are as follows: rhodopsin (ε280nm = 61,800 M-1cm-1, 
ε380nm = 42,000 M-1cm-1), transducin (ε280nm = 93,270 M-1cm-1) and MSP1D1ΔH5 (ε280nm 
= 21,430 M-1cm-1). 
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